Skip to main content
eLife logoLink to eLife
. 2025 May 22;13:RP101714. doi: 10.7554/eLife.101714

Periosteal skeletal stem cells can migrate into the bone marrow and support hematopoiesis after injury

Tony Marchand 1,2,3,4,†,, Kemi E Akinnola 3,4,, Shoichiro Takeishi 3,4, Maria Maryanovich 3,4, Sandra Pinho 3,4,5,6, Julien Saint-Vanne 2, Alexander Birbrair 3,4,7, Thierry Lamy 1,2, Karin Tarte 2,8, Paul Frenette 3,4,5,, Kira Gritsman 3,4,5,
Editors: Rio Sugimura9, Kathryn Song Eng Cheah10
PMCID: PMC12097789  PMID: 40401637

Abstract

Skeletal stem cells (SSCs) have been isolated from various tissues, including periosteum and bone marrow, where they exhibit key functions in bone biology and hematopoiesis, respectively. The role of periosteal SSCs (P-SSCs) in bone regeneration and healing has been extensively studied, but their ability to contribute to the bone marrow stroma is still under debate. In the present study, we characterized a mouse whole bone transplantation model that mimics the initial bone marrow necrosis and fatty infiltration seen after injury. Using this model and a lineage tracing approach, we observed the migration of P-SSCs into the bone marrow after transplantation. Once in the bone marrow, P-SSCs are phenotypically and functionally reprogrammed into bone marrow mesenchymal stem cells (BM-MSCs) that express high levels of hematopoietic stem cell niche factors such as Cxcl12 and Kitl. In addition, using ex vivo and in vivo approaches, we found that P-SSCs are more resistant to acute stress than BM-MSCs. These results highlight the plasticity of P-SSCs and their potential role in bone marrow regeneration after bone marrow injury.

Research organism: Mouse

eLife digest

Bone marrow is the soft tissue inside the bones in our bodies. It is the main production facility for new blood cells and makes billions of blood cells daily. However, like any other tissue or organ, the bone marrow can be damaged, for example, by radiation, chemotherapy drugs, or physical injuries like broken bones.

Bone marrow mesenchymal stromal cells or BM-MSCs are a key component of the bone marrow and are responsible for regulating self-renewal, and for proliferation and differentiation of a group of blood-cell producing stem cells called hematopoietic stem cells or HSCs.

A type of skeletal stem cell, the periosteal skeletal stem cells or P-SSCs, are located in a part of the bone called the periosteum, a thin tissue surrounding long bones. These cells are known to help bones regenerate and heal following a fracture. They are thought to share functional similarities with BM-MSCs. However, it is unclear if P-SSCs also support the recovery of blood cell production after damage to the bone marrow.

To find out more, Marchand, Akkinola et al. used bone tissue derived from genetically engineered mice whose P-SSCs produced a fluorescent tag. Transplanting this bone tissue into otherwise healthy mice mimicked the changes usually seen in the bone marrow after an injury. Microscopy imaging of the transplanted bone at different stages revealed that P-SSCs migrated into the bone marrow after the transplantation injury.

Once in the bone marrow, the P-SSCs developed BM-MSC-like characteristics, producing proteins known to support HSPCs. In other words, P-SSCs effectively transformed into new BM-MSCs, to the extent that the transplanted bone marrow could begin producing blood cells again. Further genetic analysis of P-SSCs and BM-MSCs showed that genes involved in stress resistance were more active in the P-SSCs. This suggests that P-SSCs are better at responding to stress, which may be helpful immediately after an injury.

Marchand, Akkinola et al. have developed a new model to study how the bone marrow repairs itself after it is damaged. These findings may help contribute to a more detailed understanding of the mechanisms behind bone marrow regeneration, as well as treatments to improve recovery following injury.

Introduction

Bone marrow mesenchymal stem cells (BM-MSCs) are rare self-renewing multipotent stromal cells which are capable of multilineage differentiation into osteoblasts, chondrocytes, and adipocytes (Caplan, 1991; Dominici et al., 2006; Frenette et al., 2013). BM-MSCs are mostly localized around the blood vessels and represent an important component of the hematopoietic stem cell (HSC) microenvironment, also referred to as the niche. BM-MSCs closely interact with HSCs and secrete factors, including the C-X-C motif chemokine ligand (CXCL12) and stem cell factor (SCF), that control their self-renewal, differentiation, and proliferation capacities (Kunisaki et al., 2013; Asada et al., 2017; Ding et al., 2012; Acar et al., 2015; Omatsu et al., 2010; Sugiyama et al., 2006). Several studies have used cell surface markers (CD51+, PDGFRα+, Sca-1+) or reporter mice (Lepr-cre, Nestin (Nes)-GFP, Ng2-cre) to describe distinct BM-MSC populations with significant overlap (Kunisaki et al., 2013; Asada et al., 2017; Ding et al., 2012; Méndez-Ferrer et al., 2010; Zhou et al., 2014; Pinho et al., 2013; Morikawa et al., 2009).

Recent studies have suggested that the periosteum, a thin layer of fibrous material that covers the surface of long bones, is a source of skeletal stem cells (SSCs) for bone regeneration (Chan et al., 2015; Duchamp de Lageneste et al., 2018; Debnath et al., 2018; Arnsdorf et al., 2009; Ortinau et al., 2019). These periosteum SSCs (P-SSCs) have been described as sharing some characteristics with BM-MSCs (Chan et al., 2015; Duchamp de Lageneste et al., 2018; Debnath et al., 2018). However, the relationship between these different stromal cell populations is poorly understood and the distinction between MSCs and SSCs remains controversial.

While the bone marrow is classically known as a major source of MSCs, the bone cortex represents a richer source of colony-forming units-fibroblasts (CFU-F) (Pinho et al., 2013; Mizoguchi et al., 2014; Blashki et al., 2016). It has been suggested that bone regeneration is mediated by both endochondral and intramembranous ossification and that the periosteum plays an important role in bone regeneration after injury (Duchamp de Lageneste et al., 2018; Debnath et al., 2018; Utvåg et al., 1996; Wang et al., 2017b; Shapiro, 2008). However, there is little information on the function of P-SSCs, aside from their crucial role in bone healing and remodeling, and whether they contribute to bone marrow regeneration.

In the present study, we developed and characterized a whole bone transplantation model to study bone marrow regeneration, in which an intact adult femur is transplanted subcutaneously into a recipient mouse (Picoli et al., 2023). Shortly after transplantation, bone marrow architecture in the transplanted femur, hereafter referred to as the graft, is severely altered with an expansion of adipocytes that mimics the fatty infiltration classically observed in the bone marrow after chemotherapy or radiation (Zhou et al., 2017). This initial destruction of the bone marrow microenvironment is followed by a progressive regeneration of blood vessels and the BM-MSCs network. The graft is progressively colonized by host-derived HSCs, allowing hematopoiesis to resume. Unexpectedly, we found that P-SSCs can migrate into the bone marrow and acquire BM-MSC niche functions, making them capable of supporting hematopoiesis through the in vivo expression of specific niche genes, such as Cxcl12 and Kitl. In addition, we found that BM-MSCs and P-SSCs display different metabolic profiles, and that P-SSCs exhibit higher resistance to transplantation-induced stress. In conclusion, our study demonstrates the high plasticity of P-SSCs and highlights their potential contribution to bone marrow stroma regeneration after injury.

Results

The whole bone transplant model recapitulates physiological regeneration of the bone marrow

In order to study the mechanisms involved in bone marrow regeneration, we employed a model system based on the subcutaneous transplantation of an intact adult femur into non-conditioned age- and sex-matched recipient mice (Figure 1A). The bone transplantation is followed by a rapid and massive depletion of bone marrow cells in the engrafted femur with a cell viability reaching below 10% at 24 hr after transplantation (Figure 1—figure supplement 1A). Notably, bone marrow necrosis following bone transplantation is associated with the replacement of hematopoietic cells in the graft femur by marrow adipocytes, similar to the effects of chemotherapy or irradiation (Zhou et al., 2017; Yamazaki and Allen, 1991; Figure 1—figure supplement 1B). Following bone transplantation, we observed a progressive increase in bone marrow cellularity over time with no significant difference in cellularity between the graft and host femurs at 5 months following transplantation (Figure 1B). Regeneration of the bone marrow compartment is associated with a reduction in adipogenic infiltration, as revealed by staining with the anti-perilipin antibody at 4-month post-transplantation (Figure 1—figure supplement 1B). Additionally, the absolute number of graft BM-MSCs, defined as CD45Ter119CD31CD51+CD140α+ cells by flow cytometry (Pinho et al., 2013), also increased over time, with no difference between the graft and host femurs at 5 months following transplantation (Figure 1B). We also observed a progressive increase in the number of LinSca1+cKit+CD48CD150+ phenotypic HSCs in the graft femur over time (Figure 1B). Although the absolute HSC numbers in the graft did not reach HSC numbers as detected in the host femur after 5 months (Figure 1B), no differences were observed in the numbers of hematopoietic progenitors or in the frequencies of hematopoietic cell populations between the host and graft femurs (Figure 1—figure supplement 1C). These data suggest that bone transplantation causes significant bone marrow injury, followed by a recovery process.

Figure 1. Whole bone transplantation is a good model to study bone marrow regeneration.

(A) Schematic and picture of the bone transplantation procedure. (B) Fold difference quantification of graft femur/host femur cellularity normalized to mean host femur cellularity. Total graft bone marrow cells, bone marrow mesenchymal stem cells (BM-MSCs) and hematopoietic stem cells (HSCs) were analyzed monthly until 5 months after bone transplantation (BT) (n = 3). Ordinary one-way ANOVA with Dunnett multiple comparisons was used to determine statistical significance. (C) Schematic illustration of the non-competitive repopulating assay after bone transplantation. (D) Donor HSC contribution of graft and host recipients at 4 weeks after bone marrow transplantation (n = 10). (E) Quantification of tri-lineage (myeloid, B lymphoid, and T lymphoid cells) engraftment 4-week post-transplantation (n = 10). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. This figure was created with BioRender.com.

Figure 1.

Figure 1—figure supplement 1. Bone marrow regeneration after transplantation.

Figure 1—figure supplement 1.

(A) Cell viability determined by flow cytometry and expressed as percentage of total Dapi- alive cells in the BM graft at steady state, 1, 3, 8, 15 days and 3 months after bone transplantation (n = 3–4). One-way ANOVA with Dunnett’s multiple comparisons test used to determine statistical significance. (B) Representative whole-mount confocal z-stack projections of host and graft femurs 1 and 4 months after transplantation. Adipocytes are stained using an anti-perilipin antibody. Scale bar = 50 µm. Three independent experiments yielded similar results. (C) Comparison of different hematopoietic progenitors’ populations between graft and host 5 months after bon transplantation (n = 4 per group). (D) Comparison of different immune cells populations between graft and host 5 months after bone transplantation (n = 4 per group). Data are represented as mean ± SEM. Unless otherwise noted, statistical significance was determined using unpaired two-tailed Student’s t-test. *p < 0.05, ****p < 0.0001.
Figure 1—figure supplement 2. Regenerated bone marrow is capable of supporting hematopoietic cells after transplantation.

Figure 1—figure supplement 2.

(A) Representative FACS plots showing gating strategy for trilineage reconstitution after bone marrow transplantation.

Hematopoiesis is a highly regulated and essential process by which all the differentiated blood cells are produced. To investigate whether functional hematopoietic progenitors fully recover in graft femurs, we performed a non-competitive bone marrow transplantation assay, in which we transplanted either graft or host bone marrow cells into lethally irradiated recipients at 5 months after bone transplantation (Figure 1C, Figure 1—figure supplement 2). The survival of lethally irradiated recipients remained equal in both groups, with 100% of recipients surviving throughout the length of the experiment. Chimerism analysis revealed robust engraftment of recipient mice with hematopoietic cells derived from the engrafted femurs, indicating that HSCs and progenitors derived from graft femurs can sustain long-term hematopoiesis upon transplantation (Figure 1D). We also observed no significant differences in donor cell contribution to myeloid or lymphoid lineages between the two groups (Figure 1E). Altogether, these data establish our bone transplantation model as a useful tool to study bone marrow and HSC-niche regeneration.

Graft BM-MSCs are graft-derived and progressively express HSC-niche factors during regeneration

Next, we aimed to determine the origin of the hematopoietic and stromal cell populations in the graft bone marrow. To achieve this, we took advantage of the Rosa26mT/mGand ubiquitin C (UBC) promoter-driven GFP mouse models, in which all cells are labeled by red and green reporters, respectively (Muzumdar et al., 2007; Liu et al., 2020). We transplanted femurs isolated from UBC-GFP mice into Rosa26mT/mG recipients and quantified endothelial cells, BM-MSCs, and hematopoietic cells in the graft (Figure 2A, B). Corroborating the results of Picoli et al., 2023, we observed that at 5 months post-transplantation, over 98% of the graft BM-MSCs originated from the graft femur, while over 99% of the hematopoietic cells in the graft originated from the host mouse (Figure 2C, D). Interestingly, endothelial cells were derived from both the host and the graft, suggesting the contribution of different progenitors. To further assess endothelial regeneration within the context of bone transplantation, we conducted a transplantation experiment in which femurs from Cdh5 (VE-cadherin)-CreER; iTdTomato (Wang et al., 2010) mice were transplanted into WT recipients. Confocal analysis was performed 15 days and 1 month after transplantation (Figure 2—figure supplement 1A, B). This revealed the presence of VE-cadherin-labeled vessels within the periosteum and crossing the cortical bone of the graft. This result demonstrates that endothelial regeneration occurs at an early stage following bone transplantation. Furthermore, when femurs from UBC-GFP mice were transplanted into Cdh5-CreER;iTdTomato mice, contributions of both recipient VE-cadherin-labeled and UBC-GFP vessels were observed 5 months later. This result once again demonstrated the dual contribution of endothelial cells to the grafted femur (Figure 2—figure supplement 1C). Furthermore, we did not detect any cells derived from the graft in the host femurs (data not shown). These results are consistent with data obtained from ossicle-based experiments, where MSC-seeded ossicles are colonized by recipient-derived hematopoietic cells (Méndez-Ferrer et al., 2010; Sacchetti et al., 2007; Friedenstein et al., 1968; Tavassoli and Crosby, 1968; Varas et al., 2000).

Figure 2. Regenerating bone marrow mesenchymal stem cells (BM-MSCs) are graft-derived and express hematopoietic stem cell (HSC)-niche factors.

(A) Schematic of a UBC-GFP femur transplanted into a mT/mG mouse. (B) Representative FACS plots showing the gating strategy to determine the origin of the different cell fractions in the graft 5 months after transplantation of a UBC-GFP femur into a mT/mG mouse. (C) Representative whole-mount confocal z-stack projections of a UBC-GFP bone transplanted into a mT/mG recipient 5 months after transplantation. Vascularization was stained with anti-CD31 and anti-CD144 antibodies. Scale bar = 100 µm (n = 2 mice). (D) Origin of graft BM-MSCs, endothelial cells (EC) and hematopoietic cells (Hemato) analyzed by flow cytometry 5 months after bone transplantation (n = 2). (E) Schematic of the Nes-GFP femur transplantation into a Nes-GFP mouse recipient. (F) Quantitative RT-PCR analysis of mRNA expression of Cxcl12 and Kitl expression relative to Gapdh in graft Nes-GFP+ BM-MSCs compared to steady-state Nes-GFP+ BM-MSCs at multiple time points after transplantation (n = 2–4 mice per time point). One-way ANOVA with Dunnett multiple comparisons was used to determine statistical significance. Data are represented as the mean ± SEM. Unless otherwise noted, statistical significance was determined using unpaired two-tailed Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001,. This figure was created with BioRender.com.

Figure 2.

Figure 2—figure supplement 1. Endothelial regeneration after bone transplantation.

Figure 2—figure supplement 1.

(A) Representative confocal image of graft VE-cadherin-cre;tdTomato femur transplanted into WT recipient 15 days after transplantation. Extracellularmatrix is labeled by an anti-periostin antibody. Scale bar = 100 μm (B) Representative confocal image of graft VE-cadherin-cre;tdTomato femur transplanted into WT recipient 1 month after transplantation. Extracellular matrix is labeled by an anti-periostin antibody. Scale bar = 50 μm (left) and 100 μm (right). (C) Representative confocal image of graft UBC-GFP femur transplanted into VE-cadherin-cre;tdTomato recipient 5 months after transplantation. Extracellular matrix is labeled by an anti-periostin antibody. Scale bar = 50 μm.
Figure 2—figure supplement 2. GFP+ bone marrow mesenchymal stem cells (BM-MSCs) express hematopoietic stem cell (HSC)-niche factors and form colonies.

Figure 2—figure supplement 2.

(A) Quantitative RT-PCR analysis of mRNA expression of Opn, Angpt1, and Vcam1 relative to Gapdh in host and graft Nes-GFP+ BM-MSCs 5 months after transplantation (n = 3–4 mice). (B) CFU-F absolute number of flushed CD45Ter119Nes-GFP+ BM-MSCs sorted from host and graft femurs 5 months after transplantation and plated at equal number and clonal densities under CFU-fibroblast (CFU-F) culture condition (n = 5 mice per group). Data are represented as mean ± SEM.

BM-MSCs are a major constituent of the hematopoietic niche, secreting maintenance factors that support HSCs and hematopoietic progenitors (Kunisaki et al., 2013; Asada et al., 2017; Ding et al., 2012; Zhou et al., 2014; Pinho and Frenette, 2019; Greenbaum et al., 2013). To test for HSC-niche supportive activity of graft BM-MSCs, we utilized Nes-GFP reporter mice to isolate BM-MSCs after bone transplantation. Previous work from our group has shown that Nes-GFP marks mouse MSCs with HSC-niche function within the bone marrow (Méndez-Ferrer et al., 2010). Since our previous analysis (Figure 2D) revealed that all of the graft BM-MSCs originate from the graft itself, we transplanted Nes-GFP femurs into Nes-GFP recipient mice and sorted CD45Ter119CD31Nes-GFP+ BM-MSCs from donor and recipient mice for analysis at different time points (Figure 2E). Since we did not detect circulation of BM-MSCs between host and graft bone marrow in our bone transplantation experiments (data not shown), this strategy allowed us to compare host and graft BM-MSCs using equivalent markers. In addition to the previously described increase over time in the absolute number of BM-MSCs in the graft femur (Figure 1B), we observed a progressive increase in the expression of the HSC-niche genes Cxcl12 and Kitl (which encodes Scf), reaching a plateau at 5-month post-transplantation (Figure 2F). Similarly, no differences were observed between host and graft femurs in the expression levels of additional niche factors, including osteopontin (Opn) (Nilsson et al., 2005; Stier et al., 2005), angiopoietin-1 (Angpt1) (Arai et al., 2004), and vascular cell adhesion molecule-1 (Vcam1) (Jacobsen et al., 1996; Papayannopoulou et al., 1998) at 5 months (Figure 2—figure supplement 2A). In this experiment, host and graft BM-MSCs also had similar CFU-F activity at 5 months (Figure 2—figure supplement 2B). Altogether, these results show that by 5 months post-bone transplantation, the niche-supportive and ex vivo clonogenic functions of graft BM-MSCs are restored and are similar to the activity of native host BM-MSCs.

P-SSCs but not BM-MSCs expand early after bone transplantation

SSCs are multipotent cells of the skeletal lineage that are important for bone development, repair, and homeostasis (Bianco and Gehron Robey, 2000; Matsushita et al., 2020). SSCs have been identified in the periosteum (P-SSCs), compact bone, and bone marrow (Méndez-Ferrer et al., 2010; Zhou et al., 2014; Duchamp de Lageneste et al., 2018; Jeffery et al., 2022). Similar to BM-MSCs, P-SSCs have been shown to have CFU-F activity and the ability to differentiate into osteoblasts, chondrocytes, and adipocytes (Chan et al., 2015; Debnath et al., 2018; Mirmalek-Sani et al., 2006). Due to the severe necrosis and depletion of the marrow cavity content that we observed following bone transplantation (Figure 1B, Figure 1—figure supplement 1A), we hypothesized that cells derived from the compact bone and/or the periosteum could potentially contribute to stromal marrow regeneration. We first analyzed the cellularity of graft bone marrow, compact bone, and periosteum at different early time points following transplantation. While the number of live cells within the bone marrow and compact bone were drastically reduced in the first 24 hr post-transplantation, we unexpectedly observed a significant but transient increase in live periosteal cells (Figure 3A, Figure 3—figure supplement 1A). Moreover, while most of the bone marrow cells were depleted shortly after transplantation, cell viability was not affected in the periosteum within this time frame (Figure 3A, Figure 3—figure supplement 1B). To quantify P-SSCs and BM-MSCs by flow cytometry, we used the combination of CD51 and CD200, as these markers have been well-validated in both tissues (Chan et al., 2015; Debnath et al., 2018; Gulati et al., 2018). Within the CD45Ter119CD31 fraction of live periosteal cells, we confirmed that CD51+CD200+ P-SSCs had the highest CFU-F activity and were also capable of trilineage differentiation (Figure 3—figure supplement 1C–E). Flow cytometric analysis confirmed an expansion of P-SSCs starting at day 3 post-transplantation and peaking at day 8 (Figure 3B, Figure 3—figure supplement 1F). These results were confirmed by confocal microscopy analysis of Nes-GFP graft femurs transplanted into WT mice and stained for Periostin, a matricellular protein highly expressed by periosteal cells (Duchamp de Lageneste et al., 2018; González-González and Alonso, 2018; Horiuchi et al., 1999; Merle and Garnero, 2012; Oshima et al., 2002). We detected an expansion of Nes-GFP+ skeletal progenitors (Tournaire et al., 2020) within the periosteum with a peak at day 8 (Figure 3C), similar to the expansion kinetics that we detected by flow cytometry. Interestingly, by day 15, we could detect Nes-GFP+ cells outside of the periosteum layer stained by an anti-periostin antibody and in the compact bone (Figure 3C).

Figure 3. P-SSCs remain viable and expand after bone transplantation, in contrast to bone marrow mesenchymal stem cells (BM-MSCs).

(A) Flow cytometric quantification of fold difference of total graft bone marrow and periosteum cellularity to total steady-state cellularity. Different time points early after transplantation were analyzed (n = 2–8). One-way ANOVA with Dunnett multiple comparisons was used to determine statistical significance. (B) Absolute number of CD45Ter119CD31CD51+CD200+ P-SSCs at steady state and 1-, 8-, and 15-day post-transplantation (n = 3–4 mice per time point). One-way ANOVA with Dunnett multiple comparisons was used to determine statistical significance. (C) Representative whole-mount confocal z-stack projections of Nes-GFP+ bone graft at steady state, 3-, 8-, and 15-day post-transplantation. Three independent experiments yielded similar results. Arrowheads point at Nes-GFP+ cells within the bone and bone marrow. Scale bar = 100 µm. (D) Total bone marrow cellularity and BM-MSC absolute number 5 months after transplantation of bones with or without intact periosteum (n = 3–4 mice per group). Data are represented as the mean ± SEM. Unless otherwise noted, statistical significance was determined using unpaired two-tailed Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Figure 3.

Figure 3—figure supplement 1. Periosteal stem cell expansion after transplantation.

Figure 3—figure supplement 1.

(A) Number of viable cells within bone marrow, bone and periosteum at steady state and 24-hr post-transplantation (n = 3 per group). (B) Cell viability determined by flow cytometry and expressed as percentage of total Dapi- alive cells in the periosteum graft at steady state, 1, 3, 8, 15 days and 3 months after bone transplantation (n = 2–4 per group). One-way ANOVA with Dunnett’s multiple comparisons test used to determine statistical significance. (C) Representative FACS plot showing gating of CD51+CD200+ P-SSCs after gating on triple negative cells (TNC: CD45Ter119CD31) fraction. (D) Absolute CFU-F number from 1000 sorted cells within various TNC subsets of the periosteum. One-way ANOVA with Dunnett’s multiple comparisons test used to determine statistical significance. (E) Representative trilineage differentiation pictures of CD51+CD200+ compared to the group with the next highest CFU-F activity (CD51+CD200 cells). Differentiation into osteoblasts, adipocytes, and chondrocytes observed using Alizarin Red, Bodipy, and Alican Blue staining, respectively. (F) Representative FACS plots of graft periosteum and bone marrow analysis gated on TNC fraction at steady state, 1-, 8-, and 15-day post-transplantation. Data are represented as mean ± SEM. Unless otherwise noted, statistical significance was determined using unpaired two-tailed Student’s t-test. *p < 0.05, **p < 0.01, ****p < 0.0001.

To evaluate the potential role of the periosteum in overall bone marrow regeneration, we compared the regenerative capacity of transplanted femurs with intact periosteum to that of femurs in which the periosteum was mechanically removed (Figure 3D). At 5 months after transplantation, total cellularity and BM-MSC number were significantly reduced in femurs lacking the periosteum, highlighting a potentially critical role for the periosteum and P-SSCs during bone marrow regeneration.

P-SSCs are more resistant to stress than BM-MSCs

Due to the ability of P-SSCs to survive bone transplantation, as opposed to BM-MSCs, we explored the intrinsic differences between BM-MSCs and P-SSCs. Using RNA sequencing, we analyzed the transcriptional differences between CD51+CD200+ P-SSCs and BM-MSCs at steady state. Gene set enrichment analysis (GSEA) revealed that P-SSCs were positively enriched for gene sets associated with stemness and negatively enriched for gene sets associated with proliferation (Figure 4A). These results are in line with qPCR analysis showing that P-SSCs express high levels of the cell cycle inhibitor genes Cdkn1a and Cdkn1c, and low levels of the cell cycle progression gene Cdk4 at steady state (Figure 4B). Additionally, flow cytometric analysis revealed that, compared to BM-MSCs, P-SSCs are less metabolically active, as shown by decreased glucose uptake as assessed by 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NDBG) (Figure 4C). This led us to hypothesize that P-SSCs are more resistant to stress than BM-MSCs.

Figure 4. Periosteal skeletal stem cells (SSCs) have a metabolic profile conferring a resistance to stress.

(A) Gene set enrichment analysis (GSEA) plots comparing P-SSCs versus bone marrow mesenchymal stem cells (BM-MSCs) at steady state (n = 3 per group). (B) Quantitative RT-PCR analysis of mRNA expression of Cdkn1a, Cdkn1c, Cdk4 relative to Actb in sorted CD45Ter119CD31CD51+CD200+ BM-MSCs and P-SSCs (n = 3–6 per group). (C) Flow cytometric analysis of glucose uptake at steady state in CD45Ter119CD31CD51+CD200+ BM-MSCs and P-SSCs (n = 5 per group). (D) Quantification of cellular reactive oxygen species (ROS) at steady state in CD45Ter119CD31CD51+CD200+ BM-MSCs and P-SSCs (n = 8 per group). (E) Quantitative RT-PCR analysis of mRNA expression of Sod1, Gls, and Gpx1 relative to Actb in sorted CD45Ter119CD31CD51+CD200+ BM-MSCs and P-SSCs (n = 3–7 per group). (F) Schematic illustration of the protocol for the in vitro apoptosis assay. BM-MSCs and P-SSCs were isolated and digested before plating in a 10-cm dish. At near confluence, cells underwent CD45 lineage depletion and plated into multi-well plates. At near confluence, medium was switched from 20% to 0% fetal bovine serum (FBS). Cells were analyzed at the time of medium switch and 12 hr. (G) Percentage of apoptotic BM-MSCs and P-SSCs cultured under 5% O2 at baseline and 12 hr after being in 0% FBS serum conditions (n = 11–12 per group). Two-way ANOVA with Tukey’s multiple comparisons test was used to determine statistical significance. Data are represented as the mean ± SEM. Unless otherwise noted, statistical significance was determined using unpaired two-tailed Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. This figure was created with BioRender.com.

Figure 4.

Figure 4—figure supplement 1. RNA sequencing analysis of periosteal skeletal stem cells (SSCs), 3-day graft periosteal and SSCs, and bone marrow MSCs.

Figure 4—figure supplement 1.

(A) 2D principal component analysis (PCA) plot showing variance between steady-state P-SSCs and graft P-SSCs 3 days after bone transplantation (n = 3). (B) Heatmap expression level of selected genes as defined by previous studies for hematopoietic stem cell (HSC)-niche cell and extracellular matrix genes (n = 3). (C) KEGG analysis displaying signatures that are significantly up- and down-regulated between steady-state P-SSCs and graft P-SSCs 3 days after bone transplantation (n = 3). Data are represented as mean ± SEM.
Figure 4—figure supplement 2. Comparison of periosteal skeletal stem cells (SSCs) and bone marrow MSCs.

Figure 4—figure supplement 2.

Representative FACS plots showing gating strategy for analyzing apoptosis 12 hr after switching from 20% to 0% fetal bovine serum (FBS) media.

These observations led us to also use RNA sequencing to compare steady-state P-SSCs to P-SSCs at 3 days after bone transplantation. We chose the 72 hr time point to capture the time when P-SSCs are expanding but have not yet hit the peak of expansion at around day 8. We found that while steady-state P-SSCs and day 3 graft P-SSCs are quite distinct from steady-state BM-MSCs, there is a clear variance starting to occur between the two P-SSC populations (Figure 4—figure supplement 1A). As early as 3 days post bone transplantation, we observed a downregulation of extracellular matrix (ECM) factors such as fibromodulin (Fmod) and nidogen 1 (Nid1) in the graft P-SCCs (Figure 4—figure supplement 1B). Additionally, GSEA comparing steady-state P-SSCs with graft P-SSCs, revealed an upregulation of cell cycle and DNA replication signatures and downregulation of ECM–receptor interaction and glutathione metabolism (Figure 4—figure supplement 1C), indicating that a change in the P-SSCs phenotype occurs early after bone transplantation.

Low levels of reactive oxygen species (ROS) and high expression of antioxidant enzymes are mechanisms that help stem cells to avoid stress-induced cell death (Ito and Suda, 2014; Suda et al., 2011). Thus, we measured ROS levels by staining cells with the superoxide indicator dihydroethidium (DHE). At steady state, flow cytometric analysis revealed that P-SSCs had lower levels of cellular ROS than BM-MSCs (Figure 4D). Under physiological conditions, cells can maintain low ROS levels by expressing antioxidant enzymes. Indeed, qPCR analysis revealed higher expression of three major ROS-detoxifying enzymes genes: superoxide dismutase (Sod1), glutaminase (Gls) and glutathione peroxidase (Gpx1), in sorted CD51+CD200+ P-SSCs than in CD51+CD200+ BM-MSCs (Figure 4E). Altogether, these results suggest that P-SSCs are more stress-resistant than BM-MSCs, which may leave P-SSCs poised to proliferate in response to transplantation.

The location of the periosteum on the exterior of the bone, exposing P-SSCs to a higher oxygen tension than BM-MSCs, may be a contributing factor to the observed differences in resilience between P-SSCs and BM-MSCs. Therefore, to determine whether the anatomic location of BM-MSCs and P-SSCs is the primary determinant of their differential stress response, we performed an ex vivo culture experiment designed to subject BM-MSCs and P-SSCs to equivalent levels of stress while in the same environment. After short-term ex vivo expansion of total bone marrow and periosteal cells, we performed a lineage depletion of CD45+ hematopoietic cells in both fractions. Purified P-SSCs and BM-MSCs were then maintained for 12 hr in serum-free culture media to stress the cells and mimic the nutrient deprivation that occurs immediately following bone transplantation (Figure 4F). Flow cytometric analysis of activated caspase-3/7 revealed that after 12 hr in serum-free media, BM-MSCs exhibited a significantly higher level of apoptosis compared to P-SSCs (Figure 4G, Figure 4—figure supplement 2). These results suggest that P-SSCs are more intrinsically resilient than BM-MSCs, even when they are subjected to similar stress conditions in an equivalent environment.

P-SSCs as a source of functional BM-MSCs during regeneration

As we observed that bone transplantation was followed by a depletion of bone marrow cellularity with an early expansion of P-SSCs, and that transplantation of bones without periosteum negatively impacts graft regeneration (Figure 3D), we hypothesized that proliferating P-SSCs migrate into the bone marrow and contribute to stromal regeneration. To test this hypothesis, we removed the periosteum from WT femurs and wrapped these femurs with the periosteum isolated from UBC-GFP mice (Figure 5A, B). We then transplanted these bones into WT host mice and observed GFP+ cells within the compact bone at 5 months after transplantation (Figure 5C), consistent with the well-described role of the periosteum in bone remodeling (Duchamp de Lageneste et al., 2018; Debnath et al., 2018; Julien et al., 2020). Consistent with our hypothesis, we also observed GFP+ cells enwrapping endomucin-stained sinusoids and forming a network, similar to the perivascular nature of BM-MSCs (Sugiyama et al., 2006; Méndez-Ferrer et al., 2010; Figure 5C).

Figure 5. Periosteal skeletal stem cells (SSCs) migrate into the bone marrow and support stromal regeneration after bone transplantation.

(A) Schematic of the transplantation of a WT bone enwrapped with periosteum from a UBC-GFP mouse donor into a WT recipient mouse. (B) Pictures illustrating the transplantation of a WT bone enwrapped with periosteum from a UBC-GFP mouse donor into a WT recipient mouse. (C) Representative whole-mount confocal z-stack projections of wild-type bone graft enwrapped with periosteum from a UBC-GFP mouse donor into a WT recipient mouse 5 months after transplantation. Three independent experiments yielded similar results. Right panel: arrows pointing to GFP+ periosteum located perivascularly. Scale bar = 50 µm (left panel) and 20 µm (right panel). (D) Quantification of Cxcl12 and Kitl mRNA levels relative to Gapdh in sorted control CD45Ter119CD31Nestin-GFP+ bone marrow mesenchymal stem cells (BM-MSCs), CD45Ter119CD31CD51+CD200+ P-SSCs, and CD45Ter119CD31CD51+CD200+GFP+ periosteum-derived graft BM-MSCs (n = 3–4 per group). One-way ANOVA with Tukey’s multiple comparisons was used to determine statistical significance. Data are represented as the mean ± SEM. Unless otherwise noted, statistical significance was determined using unpaired two-tailed Student’s t-test. **p < 0.01. This figure was created with BioRender.com.

Figure 5.

Figure 5—figure supplement 1. Periosteal skeletal stem cells (SSCs) migrate into the bone marrow and upregulate hematopoietic stem cell (HSC)-niche factors.

Figure 5—figure supplement 1.

(A) Representative FACs plots showing gating strategy for sorting GFP+ bone marrow mesenchymal stem cells (BM-MSCs) used in qPCR analysis. (B) Quantification of Opn and Angpt1 mRNA level relative to Gapdh in sorted control bone marrow CD45Ter119CD31Nestin-GFP+ BM-MSCs, CD45Ter119CD31CD51+CD200+ steady-state P-SSCs, and CD45Ter119CD31CD51+CD200+GFP+ graft BM-MSCs (n = 3–4 per group). One-way ANOVA used to determine statistical significance. Data are represented as mean ± SEM. Unless otherwise noted, statistical significance was determined using unpaired two-tailed Student’s t-test. *p < 0.05, **p < 0.01.

Flow cytometric analysis of the graft at 5-month post-transplantation confirmed the presence of periosteum-derived GFP+ MSCs within the bone marrow cavity (Figure 5—figure supplement 1A). Importantly, while P-SSCs do not express Cxcl12 or Kitl at steady state, periosteum-derived GFP+ BM-MSCs expressed these niche cytokines at a similar level to control sorted Nes-GFP+BM-MSCs (Figure 5D). We also quantified the expression of the niche factors Angpt1 and Opn. Similarly, we found that Angpt1 expression in the graft GFP+ BM-MSCs reached the level of control BM-MSCs, while Opn expression was higher in GFP+ BM-MSCs than in control Nes-GFP+ BM-MSCs at 5 months after transplantation (Figure 5—figure supplement 1B). However, Opn has been shown to be upregulated in settings of inflammation, injury, and migration (Denhardt et al., 2003; Wang et al., 2017a; Zou et al., 2013). Therefore, the moderate increase in Opn expression level in graft BM-MSCs compared to steady-state BM-MSCs could be due to a residual inflammatory effect of bone transplantation. These results show that P-SSCs can both migrate into the bone marrow cavity and upregulate HSC maintenance genes to support hematopoiesis.

To confirm these results, we took advantage of a previously described transgenic mouse model in which an inducible Cre is placed under the promoter of the Periostin gene (PostnMCM), hereafter referred to as PostnCre-ER (Kanisicak et al., 2016). Postn encodes the secreted matricellular protein Periostin, and is highly expressed by periosteal cells and upregulated during bone healing and formation (Duchamp de Lageneste et al., 2018). While Postn is expressed by multiple cell types, including but not limited to osteoblasts and fibroblasts (Horiuchi et al., 1999; Oshima et al., 2002; Oka et al., 2007), its high expression in P-SSCs compared with BM-MSCs (Figure 6—figure supplement 1A) makes it a useful marker to distinguish endogenous BM-MSCs from periosteum-derived BM-MSCs after bone transplantation. We crossed the PostnCre-ER line with Rosa26LSL-tdTomato reporter (Tomato) mice to be able to lineage trace P-SSCs. We transplanted femurs from PostnCre-ER;tdTomato mice into WT CD45.2 recipient mice, and then injected the host mice with tamoxifen shortly after transplantation to induce Cre recombination and Tomato expression in periosteal cells (Figure 6A). At early time points following bone transplantation, we see Tomato+ cells confined to the periosteum and located perivascularly. At 21 days after transplantation, we observe Tomato+ cells migrating into the bone marrow (Figure 6B). By 5 months after transplantation, we observe robust Tomato+ labeling in the bone marrow located around the vasculature by confocal imaging (Figure 6—figure supplement 1B), consistent with our prior observations (Figure 5C). Additionally, flow cytometric analysis revealed that an average of 85.4% (range: 65.0–94.5%) of the BM-MSCs within the engrafted bone marrow were Tomato+, indicating a periosteal origin (Figure 6C, Figure 6—figure supplement 1C).

Figure 6. Periosteum-derived graft bone marrow mesenchymal stem cells (BM-MSCs) adopt characteristics of baseline BM-MSCs, including the expression of hematopoietic stem cell (HSC)-niche factors.

(A) Schematic illustration of the transplantation of a PostnCre-ER;tdTomato femur into a WT recipient mouse. (B) Representative whole-mount confocal z-stack projections of transplanted PostnCre-ER;tdTomato femurs into a WT recipient 8-, 15-, and 21 days after transplantation. Two to three independent experiments yielded similar results. Scale bar = 100 µm. (C) Percentage of graft periosteum-derived BM-MSCs labeled Tomato+ 5 months after transplantation of a bone from a PostnCre-ER;tdTomato mouse into a WT recipient (n = 5). (D) Heatmap expression level of selected genes defined by previous studies for HSC-niche cells and extracellular matrix genes (n = 3–4). (E) Volcano plot of P-SSCs compared to graft BM-MSCs showing higher expression of HSC-niche-associated genes in graft BM-MSCs. Data are represented as the mean ± SEM. Unless otherwise noted, statistical significance was determined using unpaired two-tailed Student’s t-test. ****p < 0.0001. This figure was created with BioRender.com.

Figure 6.

Figure 6—figure supplement 1. Postn-CreER;tdTomato can be used to lineage trace periosteal skeletal stem cells (SSCs) and label periosteum-derived bone marrow mesenchymal stem cells (BM-MSCs).

Figure 6—figure supplement 1.

(A) Postn expression in sorted, steady-state CD51+CD200+ BM-MSCs and P-SSCs from CD45.2 WT mice (n = 3). (B) Representative whole-mount confocal z-stack projections of bone marrow from PostnCre-ER;tdTomato femurs into a WT recipient mouse 5 months after transplantation. Three independent experiments yielded similar results. Scale bar = 50 μm (right panel). (C) Representative FACS plots showing gating strategy for identifying Tomato+ BM-MSCs. Data are represented as mean ± SEM. Unless otherwise noted, statistical significance was determined using unpaired two-tailed Student’s t-test. **p < 0.01.
Figure 6—figure supplement 2. Single limb irradiation of PostnCre-ER;tdTomato mice.

Figure 6—figure supplement 2.

(A) Schematic diagram representing single limb irradiation of PostnCre-ER;tdTomato mice. (B) Whole-mount confocal z-stack projections of bone marrow 5 days later. White arrows point at areas of Tomato labeling along the periosteum and cortical bone. This figure was created with BioRender.com.
Figure 6—figure supplement 3. Graft Tomato+ bone marrow mesenchymal stem cells (BM-MSCs) derived from P-SSCs exhibit profile similar to that of steady-state BM-MSCs.

Figure 6—figure supplement 3.

(A) Venn diagram of RNA sequencing analysis comparing the numbers of differentially expressed genes between the groups. (B) 2D principal component analysis (PCA) plot showing variance between graft BM-MSCs at 5 months post-transplantation, and BM-MSCs and P-SSCs at steady state (n = 3–4).

We then wanted to assess our Postn mouse model using irradiation as a more physiologically relevant model of bone marrow injury, and to compare the effects of localized irradiation to femur transplantation on P-SSC plasticity. Single hindlimbs of PostnCre-ER;tdTomato mice were irradiated in order to compare the effects of irradiation within the same mouse (Figure 6—figure supplement 2A). While a clear difference in the architecture of bone marrow vasculature was observed between the non-irradiated and irradiated limbs, no difference in P-SSCs expansion or migration into the bone marrow was detected, contrasting with the findings in our femur transplant model (Figure 6—figure supplement 2B). This observation suggests that bone transplantation results in a more severe injury to the bone marrow compared to localized irradiation, thereby enabling the assessment of BM-MSCs’ recovery after more severe injury. However, it is also conceivable that stronger irradiation or a longer observation period would be necessary to observe a similar phenotype.

To examine changes in periosteum-derived BM-MSCs at the gene expression level, we performed bulk RNA sequencing on sorted CD51+CD200+Tomato+ BM-MSCs from graft PostnCre-ER;tdTomato femurs at 5 months after transplantation and on sorted steady-state CD51+CD200+ BM-MSCs and P-SSCs. Venn diagram and principal component analysis revealed that periosteum-derived graft BM-MSCs display a gene expression profile distinct from that of both steady-state BM-MSCs and steady-state P-SSCs (Figure 6—figure supplement 3A, B). Consistent with our previous tracing experiment using UBC-GFP periosteum (Figure 5D), we observed an upregulation of HSC-niche-associated maintenance genes in the 5-month-old graft BM-MSCs compared to P-SSCs at steady state (Figure 6D, E). We also observed the downregulation of Postn and other extracellular matrix-related genes, such as fibronectin (Fn1) and fibromodulin (Fmod), in periosteum-derived graft BM-MSCs compared with P-SSCs at steady state (Figure 6D, E). Taken together, our results indicate that P-SSCs can be reprogrammed and adapt a niche-supportive phenotype akin to native BM-MSCs after migrating into the bone marrow following acute stress and subsequent regeneration.

Discussion

Bone marrow regeneration is a critical process that enables the recovery of hematopoiesis after injury such as irradiation or chemotherapy. Bone marrow mesenchymal stromal cells represent a key component of the bone marrow microenvironment. These stromal cells play a crucial role in regulating the self-renewal, differentiation, and proliferative properties of HSCs. The periosteum, a thin membrane that is highly vascularized and innervated, is located on the outside of the bone. This membrane contains numerous skeletal stromal cells, which play a pivotal role in maintaining the bone tissue and facilitating post-fracture healing. While the bone marrow microenvironment at steady state has been extensively studied, the mechanisms of bone marrow regeneration and stromal recovery remain poorly understood. Furthermore, data related to the functions of P-SSC beyond their established role in bone maintenance and fracture healing remain scarce. The objective of this study was to develop and characterize a model of whole bone transplantation in order to study bone marrow regeneration in mice. In this model, severe injury to hematopoietic and stromal cells within the bone marrow is induced, allowing for the investigation of the regeneration process of both cell populations. We found that the total graft bone marrow cellularity and BM-MSC cellularity demonstrate a gradual increase over time, ultimately reaching levels comparable to steady-state levels by 5-month post-transplantation. The 5-month time point was subsequently employed for further analyses. Prior research has emphasized the significance of stromal integrity for the recovery of HSCs following irradiation or chemotherapy (Banfi et al., 2001; Lucas et al., 2013; Hérodin and Drouet, 2005). The findings of our study indicate that, while initially impacted by the stress associated with transplantation, BM-MSCs ultimately demonstrate their capacity to regenerate and sustain hematopoiesis within the engrafted femur. Furthermore, our findings indicate that hematopoietic progenitors derived from the graft femur are capable of engraftment in secondary recipient mice, thereby facilitating multi-lineage reconstitution. This model system recapitulates a recovering bone marrow microenvironment. Furthermore, it allows for genetic in vivo analysis of bone marrow regeneration. Consequently, bone transplantation can be employed as a valuable tool in future studies for investigating bone marrow regeneration.

The origin of endothelial progenitors in the bone marrow is not well defined. A recent study showed that during bone marrow regeneration after chemotherapy, sinusoidal and arteriolar vessels are derived from distinct progenitors (Xu et al., 2018). Intriguingly, in the present study, we observed that endothelial cells within the graft originate from both the graft and host, which supports the hypothesis that different progenitors contribute to the bone marrow vascular network. Therefore, it is likely that endothelial regeneration in the graft, and vascular anastomoses between the host and graft femur are also important for the hematopoietic regeneration process. Further studies are needed to clarify the respective contributions of graft- and host-derived endothelial progenitors and the relative contributions of these different progenitor populations to regeneration of the vascular network and to hematopoietic regeneration.

Our results also highlight the high resilience and plasticity of P-SSCs and reveal their potential contribution to the bone marrow stromal network and bone marrow regeneration. At steady state, P-SSC do not express HSC maintenance genes, such as Kitl and Cxcl12, and the potential capacity of P-SSC to support HSCs has not been previously addressed. Unexpectedly, our results show that in our model, P-SSCs can migrate to the bone marrow and adopt a phenotype similar to that of BM-MSCs. Therefore, it is possible that P-SSCs can be harvested and manipulated as a source of BM-MSCs. Interestingly, we did not observe a similar migration and plasticity of P-SSCs in the context of localized femur irradiation. This observation suggests that femur transplantation introduces a greater stress on the bone marrow than irradiation, and that this increased level of stress is required to induce P-SSC plasticity and migration into the bone marrow.

In accordance with our findings, a recent study employing Gli1 to trace P-SSC demonstrated the localized expression of Kitl and Cxcl12 by P-SSCs at the fracture site (Jeffery et al., 2022). However, this model was not designed to specifically address the role of P-SSC in bone marrow regeneration. Furthermore, niche-specific genes were only expressed by cells adjacent to the fracture callus. Although we did not find a baseline difference in Gli1 expression between BM-MSCs and P-SSCs in our RNA sequencing analysis, this may be due to the differences in surface markers and reporters used to identify P-SSCs and BM-MSCs. In the same study, authors did not find expression of reporters in the periosteum using the PostnCre-ER mice. It is likely that this discrepancy is attributable to differences in generation of the Postn-Cre mice used. Indeed, previous studies have demonstrated that, compared to steady state, the Postn gene is upregulated following the activation of P-SSC, which is clearly evident in the context of whole bone transplantation (Duchamp de Lageneste et al., 2018). The results of our flow cytometry and imaging analyses demonstrate that P-SSC is specifically labeled at early time points following the transplantation of grafts from PostnCre-ER mice. Therefore, we show a novel application for the use of the inducible PostnCre-ER mice to differentiate between BM-MSCs and P-SSCs in vivo. Accordingly, Duchamp de Lageneste et al. demonstrated that periostin contributes to the highly regenerative nature of P-SSCs compared to BM-MSCs (Duchamp de Lageneste et al., 2018). While previous studies have used Prx1 and Ctsk-Cre models, these models do not adequately allow the distinction between P-SSCs and BM-MSCs, likely due to their common embryonic origin (Duchamp de Lageneste et al., 2018; Debnath et al., 2018; Bianco and Gehron Robey, 2000). Periostin is a well-studied protein that has been shown to interact with extracellular matrix proteins and plays a key role in tissue regeneration and cancer progression, promoting proliferation, invasion, and anti-apoptotic signaling (González-González and Alonso, 2018; Bao et al., 2004; Butcher et al., 2007; Conway et al., 2014). Therefore, it is possible that periostin contributes to P-SSC proliferation and migration into the bone marrow, which would be an interesting area for future investigation.

Additionally, our findings illustrate the differential stress response between BM-MSCs and P-SSCs. While BM-MSCs are renowned for their resilience to stress, our findings illustrate that P-SSCs exhibit an even greater resistance to stress, which is attributed, at least in part, to their distinctive metabolic profile (Morikawa et al., 2009; Haas et al., 1969). Given that differences in apoptosis were observed between BM-MSCs and P-SSCs, even when they were cultured ex vivo under identical stress culture conditions with identical oxygen tension, it can be concluded that the observed differences between P-SSCs and BM-MSCs are due to intrinsic cellular properties rather than their anatomical location. Nevertheless, additional studies are required to elucidate the underlying mechanism responsible for the observed relative stress resistance of P-SSCs.

In conclusion, we have used a whole bone transplantation model to study bone marrow regeneration in vivo in response to acute injury using genetic tools. Our study has shown that through their high level of resilience and plasticity, P-SSCs can facilitate BM-MSC regeneration. Our data suggest that P-SSCs are able to contribute to hematopoietic cell recovery under stress conditions.

Materials and methods

Mice

Mice were maintained under specific pathogen-free conditions in a barrier facility in microisolator cages. This study complied with all ethical regulations involving experiments with mice, and the Institutional Animal Care and Use Committee of Albert Einstein College of Medicine approved all experimental procedures, based on protocol #00001101. C57BL/6J mice (stock #000664), B6.129-Postntm2.1(cre/Esr1*)Jmol/J (Kanisicak et al., 2016) mice (stock #029645), Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J (Rosa26mT/mG) mice (stock #007576), and C57BL/6-Tg(UBC-GFP)30Scha/J (stock #004353) mice were ordered from Jackson Laboratory and then bred in our facilities. Nestin-GFP (Méndez-Ferrer et al., 2010) mice were kindly provided by G. Enikolopov and then bred in our facilities. Cdh5 (VE-cadherin)-CreER; iTdTomato (Wang et al., 2010) mice were kindly provided by R. H. Adams (Max Planck Institute for Molecular Biomedicine, Germany) and then bred in our facilities. Unless otherwise specified, 6- to 12-week-old mice were used for the experiments. For all analytical and therapeutic experiments, sex-matched animals from the same age group were randomly assigned to experimental groups.

Bone transplantation procedure

Donor mice were anesthetized with isoflurane and euthanized by cervical dislocation. Femurs were isolated and preserved in an ice-cold phosphate-buffered saline (PBS) solution with 1% fetal bovine serum (FBS). Recipient mice were anesthetized with a ketamine/xylazine intraperitoneal injection (10 µl/g). Donor femurs were subcutaneously implanted in the back of the recipient mice, and the skin was sutured with a non-absorbable polyamide 5/0 silk. Mice were allowed to recover under a heat lamp until awake and monitored daily for up to a week post-surgery.

In vivo treatment

For lineage tracing experiments using femurs from Postntm2.1(cre/Esr1*)Jmol/J donor mice, tamoxifen (1 mg/mouse) was administered intraperitoneally to recipient mice twice daily for 10 consecutive days starting at day 2 post-transplantation.

Bone marrow transplantation

Non-competitive repopulation assays were performed using CD45.1 and CD45.2 mice. Recipient mice were lethally irradiated (12 Gy, two split doses) in a Cesium Mark 1 irradiator (JL Shepherd & Associates). A total of 1 × 106 CD45.2+ bone marrow nuclear cells from either the graft or host femurs were obtained at 5 months after transplantation and injected retro-orbitally into irradiated CD45.1+ mice. Mice were bled retro-orbitally every 4 weeks after bone marrow transplantation, and peripheral blood was analyzed for engraftment and repopulation up to 16 weeks.

Preparation of single-cell suspensions

To isolate P-SSCs, muscle tissue was carefully removed using scissors and intact bones were submerged for 30 min in ice-cold PBS with 1% FBS. The periosteum was carefully removed with a surgical blade, and mechanical dissociation was performed using scissors. Enzymatic dissociation was performed by incubating the periosteum fragments for 45 min at 37°C in digestion buffer (Hank’s balanced salt solution (Gibco) containing 1 mg ml−1 collagenase type IV (Gibco) and 2 mg ml−1 dispase (Gibco)) on a rotator. Bone marrow cells were obtained by flushing and dissociating using a 1-ml syringe with PBS via a 21-gauge needle. For analysis of stromal and endothelial cell populations, intact bone marrow plugs were flushed into digestion buffer using 21- or 25-gauge needles and incubated at 37°C for 30 min with manual mixing every 10 min. After bone marrow and periosteum isolation, the remaining compact bone was crushed, mechanically dissociated using scissors as previously described (Gulati et al., 2018) and digested in the digestion buffer, rotating for 45 min at 37°C. Enzymatic digestion was stopped by adding ice-cold PEB buffer (PBS with 0.5% BSA and 2 mM EDTA).

Flow cytometry and cell sorting

For FACS analysis and sorting, red blood cells were lysed (distilled H2O containing 155 mM ammonium chloride, 10 mM potassium bicarbonate, and 0.5 M EDTA) and washed in ice-cold PEB (PBS containing 0.5% BSA and 2 mM EDTA) before staining with antibodies in PEB for 20 min on ice. Dead cells and debris were excluded by FSC (forward scatter), SSC (side scatter), and DAPI (4′,6-diamino-2-phenylindole; Sigma). FACS analyses were carried out using BD LSRII flow cytometry (BD Biosciences) and cell sorting experiments were performed using a MoFlo Astrios (Beckman Coulter). Data were analyzed with FlowJo 10.4.0 (LCC) and FACS Diva 6.1 software (BD Biosciences). Antibodies used for FACS can be found in Supplementary file 1. For metabolic assays, cells were first stained with cell surface markers prior to labeling with metabolic dyes. For cellular ROS quantification, cells were incubated with DHE (5 µM; Molecular Probes) for 20 min at 37°C in PBS. Glucose uptake quantification was performed by incubating the cells in DMEM without glucose (Gibco) containing Glutamax (1:100; Gibco) and 2-NBDG (17 µmol ml–1; Cayman Chemical Company) for 30 min at 37°C.

CFU-F assays

For CFU-F and stromal cell culture, CD45Ter119CD31CD51+CD200+ stromal cells isolated from bone marrow and periosteum were sorted and plated at a clonal density (1000 cell/well) in α-MEM (Gibco) containing 20% FBS (HyClone), 10% MesenCult Stimulatory supplement (StemCell Technologies), and 1% penicillin–streptomycin. Half of the medium was changed at day 7. Cells were cultured for 12–14 days, at the end of which the colonies were scored.

Osteogenic, adipogenic, and chondrogenic differentiation assays

Trilineage differentiation assays toward the osteogenic, adipogenic, and chondrogenic lineages were performed as previously described (Pinho et al., 2013), with minor modifications. Briefly, cells were treated with StemXVivo Osteogenic, Adipogenic, or Chondrogenic mouse differentiation media, according to the manufacturer’s instructions (R&D Systems). All cultures were maintained with 5% CO2 in a water-jacketed incubator at 37°C. Osteogenic differentiation was revealed by Alizarin Red S staining. Adipocytes were identified by the typical production of lipid droplets and Bodipy (Invitrogen) staining. Chondrocytes were revealed by Alcian Blue staining.

Ex vivo culture nutrient deprivation assay

Whole bone marrow from one femur and whole periosteum from two femurs were isolated and digested as previously described and plated in α-MEM (Gibco) containing 20% FBS (HyClone), 1% penicillin–streptomycin, 1% L-glutamine, and βFGF. The medium was changed every 3–4 days. Once a plate reached near confluence, CD45 lineage depletion was performed on both bone marrow and periosteum fractions. Cells were then counted and plated in 12- or 24-well plates at approximately 5000 cells/cm2. Once the plates reached near confluence, media was switched to α-MEM without FBS, 1% L-glutamine, and βFGF. Twelve hours after the medium was switched to 0% FBS medium, the cells were trypsinized, spun down, and stained for cell surface markers. After 4–5 days, flow cytometric apoptosis quantification was performed using the CellEvent Caspase 3/7 kit (Thermo Fisher) following the manufacturer’s recommendations.

Immunofluorescence imaging of bone sections

To stain blood vessels, anti-CD31 and anti-CD144 antibodies were injected intravenously into mice (10 μg, 20 μl of 0.5 μg μl−1) and mice were sacrificed for analysis at 10 min after injection. For frozen sections of long bones, femurs and tibias were fixed in 4% paraformaldehyde (PFA) overnight at 4°C. For cryopreservation, the bones were incubated sequentially in 10%, 20%, and 30% sucrose/PBS at 4°C for 1 hr each and embedded and flash frozen in SCEM embedding medium (SECTION-LAB). Frozen sections were prepared at 20 μm thickness with a cryostat (CM3050, Leica) using the Kawamoto’s tape transfer method (Kawamoto and Shimizu, 2000). For immunofluorescence staining, sections were rinsed with PBS, post-fixed with 4% cold PFA for 10 min, followed by blocking with 20% donkey serum (DS; Sigma) in 0.5% Triton X-100/PBS for 3 hr at room temperature (20–25°C). For perilipin staining, sections were incubated for 1 hr at room temperature in saturation buffer (PBS-DS 10%). The rabbit polyclonal anti-perilipin antibody (clone: D1D8; Cat: 9349; Cell Signaling Technology) was used at 1:100 dilution in 2% DS 0.1% Triton X-100/PBS overnight at 4°C. Periostin staining was performed using whole-mount femur imaging. The bone marrow was exposed by shaving the bone using a cryostat (CM3050, Leica). Shaved femurs were fixed 30 min at 4°C in PBS/PFA 4%. Samples were then incubated in the saturation buffer (PBS-DS 10%) during 1 hr at room temperature. Polyclonal goat anti-periostin antibody (Cat: AF2955; R&D) and monoclonal rat anti-endomucin antibodies (clone: V.7C7; Cat: sc-65495; Santa Cruz) were used at a 1:100 dilution overnight at 4°C in PBS-DS 2%. When necessary, primary antibody staining was followed by three washes with 2% DS 0.1% Triton X-100/PBS and a 30-min incubation with Alexa Fluor 568 or Alexa Fluor 488-conjugated secondary antibodies (Invitrogen) and 0.2% DAPI (Sigma).

Image acquisition

All images were acquired at room temperature using a Zeiss Axio examiner D1 microscope (Zeiss) with a confocal scanner unit (Yokogawa) and reconstructed in three dimensions with Slide Book software (Intelligent Imaging Innovations). Image analysis was performed using both Slide Book software (Intelligent Imaging Innovations) and the Fiji build of ImageJ (NIH).

Single limb irradiation

Mice were anesthetized using isoflurane chamber and kept anesthetized throughout the procedure. Mice were irradiated using the Small Animal Radiation Research Platform, SARRP (XStrahl, Surrey, UK). Whole body lead shielding protected the mice except for one hindlimb which was protruding out from under the shield and irradiated to 20 Gy for 319 s in a single fraction. Mice were left under the heat lamp until they recovered.

RNA isolation and quantitative real-time PCR

mRNA was purified using the Dynabeads mRNA DIRECT Micro Kit (Life technologies – Invitrogen) by directly sorting stromal cells into lysis buffer, and reverse transcription was performed using RNA to cDNA EcoDry Premix (Clontech – Takara Bio) following the manufacturer’s instructions. The SYBR green (Roche) method was used for quantitative PCR using the QuantStudio 6 Flex system (Applied Biosystems, Thermo Fisher). All mRNA expression levels were calculated relative to Gapdh or Actb. Supplementary file 2 lists the primer sequences used.

RNA sequencing and analysis

Total RNA from 1000 to 3000 sorted steady BM-MSCs, steady-state P-SSCs, graft P-SSCs, and graft BM-MSCs was extracted using the RNAeasy Plus Micro kit (QIAGEN) and assessed for integrity and purity using an Agilent Bioanalyzer. When applicable, RNA from two mice was combined; however, each replicate contained RNA from distinct mice. RNA-seq data generated from Illumina Novaseq6000 were processed using the following pipeline. Briefly, clean reads were mapped to the mouse genome (GRCm38) using Spliced Transcripts Alignment to a Reference (STAR 2.6.1d). Gene expression levels were calculated and differentially expressed genes were identified using DESeq2 and enriched using clusterProfiler. All RNA sequencing data are available under the SuperSeries dataset GSE222272 in GEO omnibus.

Statistical analysis

All data are presented as the mean ± SEM. N represents the number of mice in each experiment, as detailed in the figure legends. No statistical method was used to predetermine sample sizes; sample sizes were determined by previous experience with similar models of hematopoiesis, as shown in previous experiments performed in our laboratory.  Statistical significance was determined by an unpaired, two-tailed Student’s t-test to compare two groups or a one-way ANOVA with multiple group comparisons. Statistical analyses were performed, and data presented using GraphPad Prism 8 (GraphPad Software), FACS Diva 6.1 software BD Biosciences, FlowJo 10.4.0 (LLC), Slide Book Software 6.0 (Intelligent Imaging Innovations), and QuantStudio 6 Real-Time PCR Software (Applied Biosystem, Thermo Fisher). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Acknowledgements

We would like to thank Colette Prophete and Daqian Sun for technical assistance and Lydia Tesfa and the Einstein Flow Cytometry Core Facility for expert cell sort assistance. We thank Charles Brottier and Robert Dubin of the Albert Einstein College of Medicine Computational Biology core facility for their help with analysis of RNA sequencing data. This work was supported by the National Institutes of Health (NIH) Grant 5R01DK056638 (to PSF and KG), administrative supplement R01DK056638-23S1 (to KEA), R01DK112976 (to PSF), R56DK130895 (to KG), R01DK130895 (to KG), R01HL162584 (to SP), the NIH training Grant T32GM007288-50 (to KEA), and NYSTEM IIRP C029570A (to PSF). TM was supported by the Fondation ARC pour la Recherche sur le Cancer, the Association pour le Développement de l’Hématologie Oncologie, the Société Française d’Hématologie, the Centre Hospitalier Universitaire de Rennes, and the Philip Foundation. ST was supported by the Japan Society for the Promotion of Science (JSPS) Postdoctoral Fellowship for Research Abroad, the Uehara Memorial Foundation Research Fellowship, and the NYSTEM Empire State Institutional Program in Stem Cell Research. M.M. was supported by the EMBO European Commission FP7 (Marie Curie Actions; EMBOCOFUND2012, GA-2012-600394, ALTF 447-2014), by the New York Stem Cell Foundation (NYSCF) Druckenmiller fellowship, and by the American Society of Hematology (ASH) Research Restart Award. SP was also supported by a Longevity Impetus Grant from Norn Group. This work was also supported by the Albert Einstein Cancer Center core support grant P30CA013330. Experimental figure illustrations were created using BioRender. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Appendix 1

Appendix 1—key resources table.

Reagent type (species) or resource Designation Source or reference Identifiers Additional information
Strain, strain background (M. musculus) B6.129S-Postntm2.1(cre/Esr1*)Jmol/J Kanisicak et al., 2016 Strain #:029645
RRID:IMSR_JAX:029645
Strain, strain background (M. musculus) Nestin-GFP Méndez-Ferrer et al., 2010 Strain #:033927
RRID:IMSR_JAX:033927
Strain, strain background (M. musculus) Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J (RosamT/mG) Muzumdar et al., 2007 Strain #:007576
RRID:IMSR_JAX:007576
Strain, strain background (M. musculus) C57BL/6-Tg(UBC-GFP)30Scha/J Liu et al., 2020 Strain #:004353
RRID:IMSR_JAX:004353
Strain, strain background (M. musculus) Cdh5-CreER; iTdTomato H. Adams (Max Planck Institute for Molecular Biomedicine, Germany)
Strain, strain background (M. musculus) C57BL/6 The Jackson Laboratory/ Bred in lab Strain #:000664
RRID:IMSR_JAX:000664
Antibody anti-streptavidin FITC/ APC-Cy7 Invitrogen RRID:AB_10053373 (FITC), AB_10054651 (APC-Cy7) FC (1:100)
Antibody anti-CD45 APC-eFluor 780/Pacific Blue Invitrogen (APC-eFluor 780), Biolegend (Pacific Blue) APC- eFluor 780 (RRID:AB_1548781), Pacific Blue (RRID:AB_493535) Clone: 30-F11
FC (1:100)
Antibody anti-CD11b AF647 Biolegend RRID:AB_389327 Clone: M1/70
FC (1:100)
Antibody anti-CD4 PE-Cy7 Invitrogen RRID:AB_469576 Clone: GK1.5
FC (1:100)
Antibody anti-CD8a PE-Cy7 Invitrogen RRID:AB_469584 Clone: 53-6.7
FC (1:100)
Antibody anti-B220 PerCP-Cy5.5 Invitrogen RRID:AB_1107006 Clone: RA3-6B2
FC (1:100)
Antibody anti-CD45.1 PE Biolegend RRID:AB_389327 Clone: A20
FC (1:100)
Antibody anti-CD45.2 FITC Biolegend RRID:AB_313442 Clone: 104
FC (1:100)
Antibody anti-CD144 AF647 Biolegend RRID:AB_10568319 Clone: BV13
FC (1:100)
IF (1:10)
Antibody anti-Gr-1 APC-eFluor 780 Invitrogen RRID:AB_2534437 Clone: RB6-8C5
FC (1:100)
Antibody anti-Ter119 Pacific Blue/ APC-eFlour 780 Biolegend (Pacific Blue), Invitrogen (APC- eFluor 780) RRID:AB_1548786 (APC- eFluor 780), AB_225116 (Pacific Blue) Clone: Ter-119
FC (1:100)
Antibody anti-CD31 PE-Cy7/AF647 Biolegend RRID:AB_830756 (PE-Cy7), AB_493410 (AF647) Clone: 390
FC (1:100)
IF (1:10)
Antibody anti-CD51 biotin/ PE Biolegend (biotin), Invitrogen (PE) RRID:AB_313072 (biotin), AB_465704 (PE) Clone: RMV-7
FC (1:100)
Antibody anti-CD200 APC Biolegend RRID:AB_10900447 Clone: OX-90
FC (1:100)
Antibody Anti-perilipin rabbit polyclonal Cell Signalling Technology Catalog #: 9349 Clone D1D8
IF (1:100)
Antibody Anti-periostin goat polyclonal R&D Catalog #: AF2955 IF (1:100)
Antibody Anti-endomucin rat monocloncal Santa Cruz Catalog #: sc-65495 Clone: V.7C7
(1:100)
Chemical compound Collagenase Type IV Gibco Catalog #: 17104019
Chemical compound Dispase II Gibco Catalog #: 17105041
Chemical compound Glutamax Gibco Catalog #: 35050061 (1:100)
Chemical compound 10% MesenCult Stimulatory Supplement StemCell Technologies Catalog #: 05402
Chemical compound 2-NDBG Cayman Chemical Company Catalog #: 11046
Chemical compound SCEM embedding media Section-lab Kawamoto and Shimizu, 2000
Chemical Compound StemXVivo Osteogenic/Adipogenic Base media R&D Systems Catalog #: CCM007
Chemical Compound StemXVivo Chondrogenic Base Media R&D Systems Catalog #: CCM005
Chemical Compound StemXVivo Osteogenic Supplement R&D Systems Catalog #: CCM009
Chemical Compound StemXVivo Chondrogenic Supplement R&D Systems Catalog #: CCM006
Chemical Compound StemXVivo Adipogenic Supplement R&D Systems Catalog #: CCM011
Commercial assay, kit Bodipy 493/503 Invitrogen Catalog #: D3922
Commercial assay, kit RNA to cDNA EcoDry Premix Clontech – Takara Bio Catalog #: 639543
Commercial assay, kit CellEvent Caspase 3/7 Green Thermo Fisher Catalog #: C10423
Commercial assay, kit RNAeasy Plus Micro Kit QIAGEN Catalog #: 74034
Commercial assay, kit Dynabeads mRNA DIRECT Micro Kit Invitrogen Invitrogen 61021
Sequence-based reagent Cxcl12_F This paper PCR primer 5′-CGCCAAGGTCGTCGCCG-3′
Sequence-based reagent Cxcl12_R This paper PCR primer 5′-TTGGCTCTGGCGATGTGGC-3′
Sequence-based reagent Kitl_F This paper PCR primer 5′-CCCTGAAGACTCGGGCCTA-3′
Sequence-based reagent Kitl_R This paper PCR primer 5′-CAATTACAAGCGAAATGAGAGCC-3′
Sequence-based reagent Opn_F This paper PCR primer 5′-AGCAAGAAACTCTTCCAAGCAA-3′
Sequence-based reagent Opn_R This paper PCR primer 5′-GTGAGATTCGTCAGATTCATCCG-3′
Sequence-based reagent Angpt1_F This paper PCR primer 5′-CTCGTCAGACATTCATCATCCAG-3′
Sequence-based reagent Angpt1_R This paper PCR primer 5′-CACCTTCTTTAGTGCAAAGGCT-3′
Sequence-based reagent Vcam1_F This paper PCR primer 5′-GACCTGTTCCAGCGAGGGTCTA-3′
Sequence-based reagent Vcam1_R This paper PCR primer 5′-CTTCCATCCTCATAGCAATTAAGGTG-3′
Sequence-based reagent Cdkn1a_F This paper PCR primer 5′-CCTGGTGATGTCCGACCTG-3′
Sequence-based reagent Cdkn1a_R This paper PCR primer 5′-CCATGAGCGCATCGCAATC-3′
Sequence-based reagent Cdkn1c_F This paper PCR primer 5′-CGAGGAGCAGGACGAGAATC-3′
Sequence-based reagent Cdkn1c_R This paper PCR primer 5′-GAAGAAGTCGTTCGCATTGGC-3′
Sequence-based reagent Cdk4_F This paper PCR primer 5′-ATGGCTGCCACTCGATATGAA 3′
Sequence-based reagent Cdk4_R This paper PCR primer 5′-TCCTCCATTAGGAACTCTCACAC-3′
Sequence-based reagent Sod1_F This paper PCR primer 5′-TGGTGGTCCATGAGAAACAA-3′
Sequence-based reagent Sod1_R This paper PCR primer 5′-GTTTACTGCGCAATCCCAAT-3′
Sequence-based reagent Gls_F This paper PCR primer 5′-TTCGCCCTCGGAGATCCTAC-3′
Sequence-based reagent Gls_R This paper PCR primer 5′-CCAAGCTAGGTAACAGACCCT-3′
Sequence-based reagent Gpx1_F This paper PCR primer 5′-AGTCCACCGTGTATGCCTTCT-3′
Sequence-based reagent Gpx1_R This paper PCR primer 5′-GAGACGCGACATTCTCAATGA-3′
Sequence-based reagent Postn_F This paper PCR primer 5′-CCTGCCCTTATATGCTCTGCT-3′
Sequence-based reagent Postn_R This paper PCR primer 5′-AAACATGGTCAATAGGCATCACT-3′
Sequence-based reagent Gapdh_F This paper PCR primer 5′-TGTGTCCGTCGTGGATCTGA-3′
Sequence-based reagent Gapdh_R This paper PCR primer 5′-CCTGCTTCACCACCTTCTTGA-3′
Sequence-based reagent Actb_F This paper PCR primer 5′-GCTTCTTTGCAGCTCCTTCGT-3′
Sequence-based reagent Actb_R This paper PCR primer 5′-ATCGTCATCCATGCCGAACT-3′
Other DAPI Sigma Prod #: D9542

Funding Statement

The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.

Contributor Information

Tony Marchand, Email: tony.marchand@chu-rennes.fr.

Kira Gritsman, Email: kira.gritsman@einsteinmed.edu.

Rio Sugimura, The University of Hong Kong, Hong Kong.

Kathryn Song Eng Cheah, University of Hong Kong, Hong Kong.

Funding Information

This paper was supported by the following grants:

  • National Institute of Diabetes and Digestive and Kidney Diseases 5R01DK056638 to Paul Frenette, Kira Gritsman.

  • National Institute of Diabetes and Digestive and Kidney Diseases R01DK056638-23S1 to Kemi E Akinnola.

  • National Institute of Diabetes and Digestive and Kidney Diseases R56DK130895 to Kira Gritsman.

  • National Institute of Diabetes and Digestive and Kidney Diseases R01DK130895 to Kira Gritsman.

  • National Heart, Lung, and Blood Institute R01HL162584 to Sandra Pinho.

  • National Institute of General Medical Sciences T32GM007288-50 to Kemi E Akinnola.

  • New York State Stem Cell Science IIRP C029570A to Paul Frenette.

  • Fondation ARC pour la Recherche sur le Cancer to Tony Marchand.

  • Association pour le Développement de l'Hématologie Oncologie to Tony Marchand.

  • Société Française d'Hématologie to Tony Marchand.

  • Centre Hospitalier Universitaire de Rennes to Tony Marchand.

  • Philip Foundation to Tony Marchand.

  • Japan Society for the Promotion of Science to Shoichiro Takeishi.

  • Uehara Memorial Foundation to Shoichiro Takeishi.

  • New York State Stem Cell Science to Shoichiro Takeishi.

  • EMBO European Commission FP7 EMBOCOFUND2012 to Maria Maryanovich.

  • New York Stem Cell Foundation to Maria Maryanovich.

  • American Society of Hematology to Maria Maryanovich.

  • Norn Group to Sandra Pinho.

  • NCI P30CA013330 to Kira Gritsman.

  • EMBO European Commission FP7 Marie Curie Actions to Maria Maryanovich.

Additional information

Competing interests

No competing interests declared.

Author contributions

Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing.

Conceptualization, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing.

Formal analysis, Investigation, Methodology, Writing – original draft.

Conceptualization, Formal analysis, Investigation, Visualization, Writing – original draft.

Formal analysis, Investigation, Visualization, Writing – original draft.

Software, Formal analysis, Validation, Visualization, Writing – original draft.

Conceptualization, Methodology.

Investigation, Visualization.

Conceptualization, Supervision, Writing – original draft.

Conceptualization, Resources, Supervision, Funding acquisition, Visualization.

Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Visualization, Writing – original draft, Project administration, Writing – review and editing.

Ethics

This study complied with all ethical regulations involving experiments with mice, and the Institutional Animal Care and Use Committee of Albert Einstein College of Medicine approved all experimental procedures, based on IACUC protocol #00001101.

Additional files

MDAR checklist
Supplementary file 1. Antibodies used in flow cytometry experiments.
Supplementary file 2. Sequences of primers used for RT-PCR .
elife-101714-supp2.docx (15.9KB, docx)

Data availability

All RNA sequencing data are available under the SuperSeries dataset GSE222272 in GEO omnibus.

The following dataset was generated:

Marchand T, Akinnola M. 2023. Periosteal skeletal stem cells can migrate into the bone marrow and support hematopoiesis after injury. NCBI Gene Expression Omnibus. GSE222272

References

  1. Acar M, Kocherlakota KS, Murphy MM, Peyer JG, Oguro H, Inra CN, Jaiyeola C, Zhao Z, Luby-Phelps K, Morrison SJ. Deep imaging of bone marrow shows non-dividing stem cells are mainly perisinusoidal. Nature. 2015;526:126–130. doi: 10.1038/nature15250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, Ito K, Koh GY, Suda T. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004;118:149–161. doi: 10.1016/j.cell.2004.07.004. [DOI] [PubMed] [Google Scholar]
  3. Arnsdorf EJ, Jones LM, Carter DR, Jacobs CR. The periosteum as a cellular source for functional tissue engineering. Tissue Engineering. Part A. 2009;15:2637–2642. doi: 10.1089/ten.TEA.2008.0244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Asada N, Kunisaki Y, Pierce H, Wang Z, Fernandez NF, Birbrair A, Ma’ayan A, Frenette PS. Differential cytokine contributions of perivascular haematopoietic stem cell niches. Nature Cell Biology. 2017;19:214–223. doi: 10.1038/ncb3475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Banfi A, Bianchi G, Galotto M, Cancedda R, Quarto R. Bone marrow stromal damage after Chemo/Radiotherapy: occurrence. Consequences and Possibilities of Treatment. Leukemia & Lymphoma. 2001;42:863–870. doi: 10.3109/10428190109097705. [DOI] [PubMed] [Google Scholar]
  6. Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang X-F. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell. 2004;5:329–339. doi: 10.1016/s1535-6108(04)00081-9. [DOI] [PubMed] [Google Scholar]
  7. Bianco P, Gehron Robey P. Marrow stromal stem cells. The Journal of Clinical Investigation. 2000;105:1663–1668. doi: 10.1172/JCI10413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Blashki D, Murphy MB, Ferrari M, Simmons PJ, Tasciotti E. Mesenchymal stem cells from cortical bone demonstrate increased clonal incidence, potency, and developmental capacity compared to their bone marrow-derived counterparts. Journal of Tissue Engineering. 2016;7:2041731416661196. doi: 10.1177/2041731416661196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Butcher JT, Norris RA, Hoffman S, Mjaatvedt CH, Markwald RR. Periostin promotes atrioventricular mesenchyme matrix invasion and remodeling mediated by integrin signaling through Rho/PI 3-kinase. Developmental Biology. 2007;302:256–266. doi: 10.1016/j.ydbio.2006.09.048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Caplan AI. Mesenchymal stem cells. Journal of Orthopaedic Research. 1991;9:641–650. doi: 10.1002/jor.1100090504. [DOI] [PubMed] [Google Scholar]
  11. Chan CKF, Seo EY, Chen JY, Lo D, McArdle A, Sinha R, Tevlin R, Seita J, Vincent-Tompkins J, Wearda T, Lu W-J, Senarath-Yapa K, Chung MT, Marecic O, Tran M, Yan KS, Upton R, Walmsley GG, Lee AS, Sahoo D, Kuo CJ, Weissman IL, Longaker MT. Identification and specification of the mouse skeletal stem cell. Cell. 2015;160:285–298. doi: 10.1016/j.cell.2014.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Conway SJ, Izuhara K, Kudo Y, Litvin J, Markwald R, Ouyang G, Arron JR, Holweg CTJ, Kudo A. The role of periostin in tissue remodeling across health and disease. Cellular and Molecular Life Sciences. 2014;71:1279–1288. doi: 10.1007/s00018-013-1494-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Debnath S, Yallowitz AR, McCormick J, Lalani S, Zhang T, Xu R, Li N, Liu Y, Yang YS, Eiseman M, Shim J-H, Hameed M, Healey JH, Bostrom MP, Landau DA, Greenblatt MB. Discovery of a periosteal stem cell mediating intramembranous bone formation. Nature. 2018;562:133–139. doi: 10.1038/s41586-018-0554-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Denhardt DT, Mistretta D, Chambers AF, Krishna S, Porter JF, Raghuram S, Rittling SR. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clinical & Experimental Metastasis. 2003;20:77–84. doi: 10.1023/a:1022550721404. [DOI] [PubMed] [Google Scholar]
  15. Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012;481:457–462. doi: 10.1038/nature10783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells: The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–317. doi: 10.1080/14653240600855905. [DOI] [PubMed] [Google Scholar]
  17. Duchamp de Lageneste O, Julien A, Abou-Khalil R, Frangi G, Carvalho C, Cagnard N, Cordier C, Conway SJ, Colnot C. Periosteum contains skeletal stem cells with high bone regenerative potential controlled by Periostin. Nature Communications. 2018;9:773. doi: 10.1038/s41467-018-03124-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Frenette PS, Pinho S, Lucas D, Scheiermann C. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annual Review of Immunology. 2013;31:285–316. doi: 10.1146/annurev-immunol-032712-095919. [DOI] [PubMed] [Google Scholar]
  19. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow: Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6:230–247. [PubMed] [Google Scholar]
  20. González-González L, Alonso J. Periostin: a matricellular protein with multiple functions in cancer development and progression. Frontiers in Oncology. 2018;8:225. doi: 10.3389/fonc.2018.00225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Greenbaum A, Hsu Y-MS, Day RB, Schuettpelz LG, Christopher MJ, Borgerding JN, Nagasawa T, Link DC. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature. 2013;495:227–230. doi: 10.1038/nature11926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Gulati GS, Murphy MP, Marecic O, Lopez M, Brewer RE, Koepke LS, Manjunath A, Ransom RC, Salhotra A, Weissman IL, Longaker MT, Chan CKF. Isolation and functional assessment of mouse skeletal stem cell lineage. Nature Protocols. 2018;13:1294–1309. doi: 10.1038/nprot.2018.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Haas RJ, Bohne F, Fliedner TM. On the development of slowly-turning-over cell types in neonatal rat bone marrow (studies utilizing the complete tritiated thymidine labelling method complemented by C-14 thymidine administration) Blood. 1969;34:791–805. doi: 10.1182/blood.V34.6.791.791. [DOI] [PubMed] [Google Scholar]
  24. Hérodin F, Drouet M. Cytokine-based treatment of accidentally irradiated victims and new approaches. Experimental Hematology. 2005;33:1071–1080. doi: 10.1016/j.exphem.2005.04.007. [DOI] [PubMed] [Google Scholar]
  25. Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, Toyama Y, Bonewald LF, Kudo A. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. Journal of Bone and Mineral Research. 1999;14:1239–1249. doi: 10.1359/jbmr.1999.14.7.1239. [DOI] [PubMed] [Google Scholar]
  26. Ito K, Suda T. Metabolic requirements for the maintenance of self-renewing stem cells. Nature Reviews. Molecular Cell Biology. 2014;15:243–256. doi: 10.1038/nrm3772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Jacobsen K, Kravitz J, Kincade PW, Osmond DG. Adhesion receptors on bone marrow stromal cells: in vivo expression of vascular cell adhesion molecule-1 by reticular cells and sinusoidal endothelium in normal and gamma-irradiated mice. Blood. 1996;87:73–82. doi: 10.1182/blood.V87.1.73.73. [DOI] [PubMed] [Google Scholar]
  28. Jeffery EC, Mann TLA, Pool JA, Zhao Z, Morrison SJ. Bone marrow and periosteal skeletal stem/progenitor cells make distinct contributions to bone maintenance and repair. Cell Stem Cell. 2022;29:1547–1561. doi: 10.1016/j.stem.2022.10.002. [DOI] [PubMed] [Google Scholar]
  29. Julien A, Perrin S, Duchamp de Lageneste O, Carvalho C, Bensidhoum M, Legeai-Mallet L, Colnot C. FGFR3 in periosteal cells drives cartilage-to-bone transformation in bone repair. Stem Cell Reports. 2020;15:955–967. doi: 10.1016/j.stemcr.2020.08.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Kanisicak O, Khalil H, Ivey MJ, Karch J, Maliken BD, Correll RN, Brody MJ, J Lin S-C, Aronow BJ, Tallquist MD, Molkentin JD. Genetic lineage tracing defines myofibroblast origin and function in the injured heart. Nature Communications. 2016;7:12260. doi: 10.1038/ncomms12260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Kawamoto T, Shimizu M. A method for preparing 2- to 50-micron-thick fresh-frozen sections of large samples and undecalcified hard tissues. Histochemistry and Cell Biology. 2000;113:331–339. doi: 10.1007/s004180000149. [DOI] [PubMed] [Google Scholar]
  32. Kunisaki Y, Bruns I, Scheiermann C, Ahmed J, Pinho S, Zhang D, Mizoguchi T, Wei Q, Lucas D, Ito K, Mar JC, Bergman A, Frenette PS. Arteriolar niches maintain haematopoietic stem cell quiescence. Nature. 2013;502:637–643. doi: 10.1038/nature12612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Liu S, Lockhart JR, Fontenard S, Berlett M, Ryan TM. Mapping the chromosomal insertion site of the GFP transgene of UBC-GFP Mice to the MHC Locus. Journal of Immunology. 2020;204:1982–1987. doi: 10.4049/jimmunol.1901338. [DOI] [PubMed] [Google Scholar]
  34. Lucas D, Scheiermann C, Chow A, Kunisaki Y, Bruns I, Barrick C, Tessarollo L, Frenette PS. Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration. Nature Medicine. 2013;19:695–703. doi: 10.1038/nm.3155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Matsushita Y, Nagata M, Kozloff KM, Welch JD, Mizuhashi K, Tokavanich N, Hallett SA, Link DC, Nagasawa T, Ono W, Ono N. A Wnt-mediated transformation of the bone marrow stromal cell identity orchestrates skeletal regeneration. Nature Communications. 2020;11:332. doi: 10.1038/s41467-019-14029-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Méndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, Scadden DT, Ma’ayan A, Enikolopov GN, Frenette PS. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466:829–834. doi: 10.1038/nature09262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Merle B, Garnero P. The multiple facets of periostin in bone metabolism. Osteoporosis International. 2012;23:1199–1212. doi: 10.1007/s00198-011-1892-7. [DOI] [PubMed] [Google Scholar]
  38. Mirmalek-Sani SH, Tare RS, Morgan SM, Roach HI, Wilson DI, Hanley NA, Oreffo ROC. Characterization and multipotentiality of human fetal femur-derived cells: implications for skeletal tissue regeneration. STEM CELLS. 2006;24:1042–1053. doi: 10.1634/stemcells.2005-0368. [DOI] [PubMed] [Google Scholar]
  39. Mizoguchi T, Pinho S, Ahmed J, Kunisaki Y, Hanoun M, Mendelson A, Ono N, Kronenberg HM, Frenette PS. Osterix marks distinct waves of primitive and definitive stromal progenitors during bone marrow development. Developmental Cell. 2014;29:340–349. doi: 10.1016/j.devcel.2014.03.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Morikawa S, Mabuchi Y, Kubota Y, Nagai Y, Niibe K, Hiratsu E, Suzuki S, Miyauchi-Hara C, Nagoshi N, Sunabori T, Shimmura S, Miyawaki A, Nakagawa T, Suda T, Okano H, Matsuzaki Y. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. The Journal of Experimental Medicine. 2009;206:2483–2496. doi: 10.1084/jem.20091046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-fluorescent Cre reporter mouse. Genesis. 2007;45:593–605. doi: 10.1002/dvg.20335. [DOI] [PubMed] [Google Scholar]
  42. Nilsson SK, Johnston HM, Whitty GA, Williams B, Webb RJ, Denhardt DT, Bertoncello I, Bendall LJ, Simmons PJ, Haylock DN. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood. 2005;106:1232–1239. doi: 10.1182/blood-2004-11-4422. [DOI] [PubMed] [Google Scholar]
  43. Oka T, Xu J, Kaiser RA, Melendez J, Hambleton M, Sargent MA, Lorts A, Brunskill EW, Dorn GW, Conway SJ, Aronow BJ, Robbins J, Molkentin JD. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circulation Research. 2007;101:313–321. doi: 10.1161/CIRCRESAHA.107.149047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Omatsu Y, Sugiyama T, Kohara H, Kondoh G, Fujii N, Kohno K, Nagasawa T. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity. 2010;33:387–399. doi: 10.1016/j.immuni.2010.08.017. [DOI] [PubMed] [Google Scholar]
  45. Ortinau LC, Wang H, Lei K, Deveza L, Jeong Y, Hara Y, Grafe I, Rosenfeld SB, Lee D, Lee B, Scadden DT, Park D. Identification of functionally distinct Mx1+αSMA+ periosteal skeletal stem cells. Cell Stem Cell. 2019;25:784–796. doi: 10.1016/j.stem.2019.11.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Oshima A, Tanabe H, Yan T, Lowe GN, Glackin CA, Kudo A. A novel mechanism for the regulation of osteoblast differentiation: transcription of periostin, A member of the fasciclin I family, is regulated by the bHLH transcription factor, twist. Journal of Cellular Biochemistry. 2002;86:792–804. doi: 10.1002/jcb.10272. [DOI] [PubMed] [Google Scholar]
  47. Papayannopoulou T, Priestley GV, Nakamoto B. Anti-VLA4/VCAM-1-induced mobilization requires cooperative signaling through the kit/mkit ligand pathway. Blood. 1998;91:2231–2239. doi: 10.1182/blood.V91.7.2231. [DOI] [PubMed] [Google Scholar]
  48. Picoli CC, Martins PR, Wong XLC, Righi T, Guimarães PPG, Pinto MCX, Amorim JH, Azevedo VAC, Pereira SR, Kanashiro A, Cruz FC, Resende RR, Mintz A, Frenette PS, Birbrair A. Whole bone subcutaneous transplantation as a strategy to study precisely the bone marrow niche. Stem Cell Reviews and Reports. 2023;19:906–927. doi: 10.1007/s12015-022-10496-9. [DOI] [PubMed] [Google Scholar]
  49. Pinho S, Lacombe J, Hanoun M, Mizoguchi T, Bruns I, Kunisaki Y, Frenette PS. PDGFRα and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. The Journal of Experimental Medicine. 2013;210:1351–1367. doi: 10.1084/jem.20122252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Pinho S, Frenette PS. Haematopoietic stem cell activity and interactions with the niche. Nature Reviews. Molecular Cell Biology. 2019;20:303–320. doi: 10.1038/s41580-019-0103-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I, Tagliafico E, Ferrari S, Robey PG, Riminucci M, Bianco P. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007;131:324–336. doi: 10.1016/j.cell.2007.08.025. [DOI] [PubMed] [Google Scholar]
  52. Shapiro F. Bone development and its relation to fracture repair: The role of mesenchymal osteoblasts and surface osteoblasts. European Cells & Materials. 2008;15:53–76. doi: 10.22203/ecm.v015a05. [DOI] [PubMed] [Google Scholar]
  53. Stier S, Ko Y, Forkert R, Lutz C, Neuhaus T, Grünewald E, Cheng T, Dombkowski D, Calvi LM, Rittling SR, Scadden DT. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. The Journal of Experimental Medicine. 2005;201:1781–1791. doi: 10.1084/jem.20041992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Suda T, Takubo K, Semenza GL. Metabolic regulation of hematopoietic stem cells in the hypoxic niche. Cell Stem Cell. 2011;9:298–310. doi: 10.1016/j.stem.2011.09.010. [DOI] [PubMed] [Google Scholar]
  55. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006;25:977–988. doi: 10.1016/j.immuni.2006.10.016. [DOI] [PubMed] [Google Scholar]
  56. Tavassoli M, Crosby WH. Transplantation of marrow to extramedullary sites. Science. 1968;161:54–56. doi: 10.1126/science.161.3836.54. [DOI] [PubMed] [Google Scholar]
  57. Tournaire G, Stegen S, Giacomini G, Stockmans I, Moermans K, Carmeliet G, van Gastel N. Nestin-GFP transgene labels skeletal progenitors in the periosteum. Bone. 2020;133:115259. doi: 10.1016/j.bone.2020.115259. [DOI] [PubMed] [Google Scholar]
  58. Utvåg SE, Grundnes O, Reikeraos O. Effects of periosteal stripping on healing of segmental fractures in rats. Journal of Orthopaedic Trauma. 1996;10:279–284. doi: 10.1097/00005131-199605000-00009. [DOI] [PubMed] [Google Scholar]
  59. Varas F, Grande T, Ramírez A, Bueren JA. Implantation of bone marrow beneath the kidney capsule results in transfer not only of functional stroma but also of hematopoietic repopulating cells. Blood. 2000;96:2307–2309. [PubMed] [Google Scholar]
  60. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, Adams S, Davy A, Deutsch U, Lüthi U, Barberis A, Benjamin LE, Mäkinen T, Nobes CD, Adams RH. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature. 2010;465:483–486. doi: 10.1038/nature09002. [DOI] [PubMed] [Google Scholar]
  61. Wang W, Li P, Li W, Jiang J, Cui Y, Li S, Wang Z. Osteopontin activates mesenchymal stem cells to repair skin wound. PLOS ONE. 2017a;12:e0185346. doi: 10.1371/journal.pone.0185346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Wang T, Zhang X, Bikle DD. Osteogenic differentiation of periosteal cells during fracture healing. Journal of Cellular Physiology. 2017b;232:913–921. doi: 10.1002/jcp.25641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Xu C, Gao X, Wei Q, Nakahara F, Zimmerman SE, Mar J, Frenette PS. Stem cell factor is selectively secreted by arterial endothelial cells in bone marrow. Nature Communications. 2018;9:2449. doi: 10.1038/s41467-018-04726-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Yamazaki K, Allen TD. Ultrastructural and morphometric alterations in bone marrow stromal tissue after 7 Gy irradiation. Blood Cells. 1991;17:527–549. [PubMed] [Google Scholar]
  65. Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell. 2014;15:154–168. doi: 10.1016/j.stem.2014.06.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Zhou BO, Yu H, Yue R, Zhao Z, Rios JJ, Naveiras O, Morrison SJ. Bone marrow adipocytes promote the regeneration of stem cells and haematopoiesis by secreting SCF. Nature Cell Biology. 2017;19:891–903. doi: 10.1038/ncb3570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Zou C, Luo Q, Qin J, Shi Y, Yang L, Ju B, Song G. Osteopontin promotes mesenchymal stem cell migration and lessens cell stiffness via integrin β1, FAK, and ERK pathways. Cell Biochemistry and Biophysics. 2013;65:455–462. doi: 10.1007/s12013-012-9449-8. [DOI] [PubMed] [Google Scholar]

eLife Assessment

Rio Sugimura 1

The study presents valuable insights into the role of periosteal stem cells in bone marrow regeneration. The evidence is convincing. The data broadly support their claims and in line with state-of-art methodology. Future study on their model will help to strengthen their discovery further.

Reviewer #1 (Public review):

Anonymous

Summary:

The manuscript under review investigates the role of periosteal stem cells (P-SSC) in bone marrow regeneration using a whole bone subcutaneous transplantation model. While the model is somewhat artificial, the findings were interesting, suggesting the migration of periosteal stem cells into the bone marrow and their potential to become bone marrow stromal cells. This indicates a significant plasticity of P-SSC consistent with previous reports using fracture models (Cell Stem Cell 29:1547, Dev Cell 59:1192).

Major comments from previous round of review:

(1) The authors assert that the periosteal layer was completely removed in their model, which is crucial for their conclusions. To substantiate this claim, it is recommended that the authors provide evidence of the successful removal of the entire periosteal stem cell (P-SSC) population. A colony-forming assay, with and without periosteal removal, could serve as a suitable method to demonstrate this.

(2) The observation that P-SSCs do not express Kitl or Cxcl12, while their bone marrow stromal cell (BM-MSC) derivatives do, is a key finding. To strengthen this conclusion, the authors are encouraged to repeat the experiment using Cxcl12 or Scf reporter alleles. Immunofluorescence staining that confirms the migration of periosteal cells and their transformation into Cxcl12- or Scf-reporter-positive cells would significantly enhance the paper's key conclusion.

(3) On page 8, line 20, the authors' statement regarding the detection of Periostin+ cells outside the periosteum layer could be misinterpreted due to the use of the periostin antibody. Given that periostin is an extracellular matrix protein, the staining may not accurately represent Periostin-expressing cells but rather the presence of periostin in the extracellular matrix. The authors should revise this section for greater precision.

Comments on revised version:

My comments from the previous round of review have mostly been addressed.

Reviewer #2 (Public review):

Anonymous

Summary:

The authors have established a femur graft model that allows the study of hematopoietic regeneration following transplantation. They have extensively characterized this model, demonstrating the loss of hematopoietic cells from the donor femur following transplantation, with recovery of hematopoiesis from recipient cells. They also show evidence that BM MSCs present in the graft following transplantation are graft-derived. They have utilized this model to show that following transplantation, periosteal cells respond by first expanding, then giving rise to more periosteal SSCs, then migrating into the marrow to give rise to BM MSCs.

Strengths:

These studies are notable in several ways: (1) establishment of a novel femur graft model for the study of hematopoiesis; (2) Use of lineage tracing and surgery models to demonstrate that periosteal cells can give rise to BM MSCs.

Weaknesses:

There are a few weaknesses. First, the authors do not definitively demonstrate the requirement of periosteal SSC movement into the BM cavity for hematopoietic recovery. Hematopoiesis recovers significantly before 5 months, even before significant P-SSC movement has been shown, and hematopoiesis recovers significantly even when periosteum has been stripped. Second, it is not clear how the periosteum is changing in the grafts. Which cells are expanding is unclear, and it is not clear if these cells have already adopted a more MSC-like phenotype prior to entering the marrow space. Indeed, given the presence of host-derived endothelial cells in the BM, these studies are reminiscent of prior studies from this group and others that re-endothelialization of the marrow may be much more important for determining hematopoietic regeneration, rather the P-SSC migration. Third, the studies exploring the preferential depletion of BM MSCs vs P-SSCs are difficult to interpret. The single metabolic stress condition chosen was not well-justified, and the use of purified cell populations to study response to stress ex vivo may have introduced artifacts into the system.

Comments on the current version: The authors have addressed my concerns adequately

eLife. 2025 May 22;13:RP101714. doi: 10.7554/eLife.101714.3.sa3

Author response

Tony Marchand 1, Kemi E Akinnola 2, Shoichiro Takeishi 3, Maria Maryanovich 4, Sandra Pinho 5, Julien Saint-Vanne 6, Alexander Birbrair 7, Thierry Lamy 8, Karin Tarte 9, Paul Frenette 10, Kira Gritsman 11

The following is the authors’ response to the original reviews.

Public Reviews:

Reviewer #1 (Public review):

The manuscript under review investigates the role of periosteal stem cells (P-SSC) in bone marrow regeneration using a whole-bone subcutaneous transplantation model. While the model is somewhat artificial, the findings were interesting, suggesting the migration of periosteal stem cells into the bone marrow and their potential to become bone marrow stromal cells. This indicates a significant plasticity of P-SSC consistent with previous reports using fracture models (Cell Stem Cell 29:1547, Dev Cell 59:1192).

Major Concerns

(1) The authors assert that the periosteal layer was completely removed in their model, which is crucial for their conclusions. To substantiate this claim, it is recommended that the authors provide evidence of the successful removal of the entire periosteal stem cell (P-SSC) population. A colony-forming assay, with and without periosteal removal, could serve as a suitable method to demonstrate this.

We are grateful to the reviewer for this valuable suggestion. The objective of this experiment was to demonstrate that periosteal ablation impairs bone marrow regeneration, a finding that is supported by our results. We expect that ablation of the periosteum would be associated with only a partial decrease in CFU-F activity, given the presence of MSCs in the bone and in the endosteal region of the bone marrow. Therefore, CFU-F assays would be difficult to interpret in this setting. In view of the phenotype obtained, providing proof of concept of the importance of the periosteum, we do not believe that further experiments would strengthen the level of proof of this experiment.

(2) The observation that P-SSCs do not express Kitl or Cxcl12, while their bone marrow stromal cell (BM-MSC) derivatives do, is a key finding. To strengthen this conclusion, the authors are encouraged to repeat the experiment using Cxcl12 or Scf reporter alleles. Immunofluorescence staining that confirms the migration of periosteal cells and their transformation into Cxcl12- or Scf-reporter-positive cells would significantly enhance the paper's key conclusion.

Transplantation of periosteum isolated from Cxcl12 or Scf into WT bones is an excellent suggestion. Indeed, this experiment would confirm (1) the migration of periosteal SSC and (2) the expression of Cxcl12 and Scf by BM-MSCs derived from the periosteum .However, it should be noted that the current limitations in terms of available resources preclude the execution of these experiments. Moreover, the use of the PostnCreER;Tmt mice represent the optimal approach for tracking and specifically isolating BM-MSCs derived from the periosteum. The expression of Cxcl12 and Scf by BM-MSCs derived from the periosteum has been demonstrated in 2 distinct experimental models (Figures 5 and 6).

(3) On page 8, line 20, the authors' statement regarding the detection of Periostin+ cells outside the periosteum layer could be misinterpreted due to the use of the periostin antibody. Given that periostin is an extracellular matrix protein, the staining may not accurately represent Periostin-expressing cells but rather the presence of periostin in the extracellular matrix. The authors should revise this section for greater precision.

We acknowledge and appreciate the reviewer's attention to detail. This is, in fact, an error. Nestin-GFP positive periosteal SSC are seen within the periosteum marked by an anti-periostin antibody labeling the extracellular matrix of the periosteum. The manuscript has been revised to address this inaccuracy on page 9, lines 8-9.

Reviewer #2 (Public review):

Summary:

The authors have established a femur graft model that allows the study of hematopoietic regeneration following transplantation. They have extensively characterized this model, demonstrating the loss of hematopoietic cells from the donor femur following transplantation, with recovery of hematopoiesis from recipient cells. They also show evidence that BM MSCs present in the graft following transplantation are graft-derived. They have utilized this model to show that following transplantation, periosteal cells respond by first expanding, then giving rise to more periosteal SSCs, and then migrating into the marrow to give rise to BM MSCs.

Strengths:

These studies are notable in several ways:

(1) Establishment of a novel femur graft model for the study of hematopoiesis;

(2) Use of lineage tracing and surgery models to demonstrate that periosteal cells can give rise to BM MSCs.

We thank the reviewer for noting the novelty of our manuscript.

Weaknesses:

There are a few weaknesses. First, the authors do not definitively demonstrate the requirement of periosteal SSC movement into the BM cavity for hematopoietic recovery. Hematopoiesis recovers significantly before 5 months, even before significant P-SSC movement has been shown, and hematopoiesis recovers significantly even when periosteum has been stripped.

This is an important point. Notably, we can see expansion of P-SSCs by day 8 after femur transplantation and evidence of periosteum-derived SSCs in the bone marrow by day 15, before we can detect any significant hematopoietic recovery (see Figure 3A-C).

Second, it is not clear how the periosteum is changing in the grafts. Which cells are expanding is unclear, and it is not clear if these cells have already adopted a more MSC-like phenotype prior to entering the marrow space.

This is an interesting question. To examine early changes in gene expression in periosteal SSCs in grafted femurs, we performed additional RNA sequencing on host periosteal SSCs vs periosteal SSCs from grafted femurs at an earlier time point - at 3 days after femur transplantation and on host bone marrow MSCs (see new Supplementary Figure S5 A-C). At this time point the three cell populations are already distinct on the PCA plot (Figure S5A), and there is downregulation of some periosteal genes in the graft P-SSCs (Figure S5B). However, we do not yet see upregulation of Kitl or Cxcl12 or most other BM MSC genes in graft P-SSCs at this time point (Figure S5B). Furthermore, gene set enrichment analysis (GSEA) revealed upregulation of cell cycle, DNA replication and mismatch repair gene signatures, and downregulation of multiple gene signatures compared to host P-SSCs (Figure S5C). Therefore, we conclude that P-SSCs already adopt some gene expression changes early after femur transplantation, but have not yet fully differentiated into BM MSCs at this early time point. This experiment is now discussed on p.10 of the revised manuscript.

Indeed, given the presence of host-derived endothelial cells in the BM, these studies are reminiscent of prior studies from this group and others that re-endothelialization of the marrow may be much more important for determining hematopoietic regeneration, rather than the P-SSC migration.

Indeed, as previously shown by our group and others, we agree that endothelial regeneration and re-endothelialization may also play an important role in this bone marrow regeneration model. It is noteworthy that this model has the potential to serve as a valuable tool for analyzing the origin of BM endothelial cells during regeneration processes. To further illustrate the endothelial regeneration, additional images of bone sections from VE-cadherin-cre;TdTomato grafted femurs at 15 days, one month, and five months post-transplantation have been included in the new Figure S3. These images reveal extensive vascularization of the graft and proximity of UBC-GFP+ donor-derived vessels to VE-cadherin+ host-derived blood vessels in the bone marrow within one month (see Figure S2C). This observation is consistent with the timing of both BM MSC recovery and HSC recovery in the grafts, thereby suggesting the importance of endothelial recovery (see Fig. 1B). A new discussion of these findings has been included on page 6 of the revised manuscript and on page 16 in the discussion section.

Third, the studies exploring the preferential depletion of BM MSCs vs P-SSCs are difficult to interpret. The single metabolic stress condition chosen was not well-justified, and the use of purified cell populations to study response to stress ex vivo may have introduced artifacts into the system.

We chose to focus on hypoxia as the main condition in which to analyze the stress response of P-SSCs vs BM MSCs because we reasoned that due to the location of P-SSCs on the outside of the bone, these cells would be exposed to a higher oxygen tension than BM-MSCs, which are located within the bone marrow. Therefore, we wanted to determine whether this exposure to a different oxygen tension would be sufficient to explain the different properties of P-SSCs and BM MSCs. We modified the text on p.11 of the manuscript to explain the rationale for this experiment better.

Reviewer #3 (Public review):

Summary:

Marchand, Akinnola, et al. describe the use of the novel model to study BM regeneration. Here, they harvest intact femurs and subcutaneously graft them into recipient mice. Similar to standard BM regeneration models, there is a rapid decrease in cellularity followed by a gradual recovery over 5 months within the grafts. At 5 months, these grafts have robust HSC activity, similar to HSCs isolated from the host femur. They find that periosteum skeletal stem cells (p-SSCs) are the primary source of BM-MSCs within the grafted femur and that these cells are more resistant to the acute stress of grafting the femur.

Strengths:

This is an interesting manuscript that describes a novel model to study BM regeneration. The model has tremendous promise.

We thank the reviewer for highlighting the novelty and potential of our work.

Weaknesses:

The authors claim that grafting intact femurs subcutaneously is a model of BM regeneration and can be used as a replacement for gold standard BM regeneration assays such as sublethal chemo/irradiation. However, there isn't enough explanation as to how this model is equivalent or superior to the traditional models. For instance, the authors claim that this model allows for the study of "BM regeneration in vivo in response to acute injury using genetic tools." This can and has been done numerous times with established, physiologically relevant BM regeneration models. The onus is on the authors to discuss or perform the necessary experiments to justify the use of this model. For example, standard BM regeneration models involve systemic damage that is akin to therapies that require BM regeneration. How is studying the current model that provides only an acute injury more relevant and useful than other models? As it stands, it seems as if the authors could have done all the experiments demonstrating the importance of these p-SSCs in the traditional myelosuppressive BM regeneration models to be more physiologically relevant. Along these lines, the use of a standard BM regeneration model (e.g., sublethal chemo/irradiation) as a critical control is missing and should be included. Even if the control doesn't demonstrate that p-SSCs can contribute to the BM-MSC during regeneration, it will still be important because it could be the justification for using the described model to specifically study p-SSCs' regulation of BM regeneration.

We appreciate the reviewer raising this important point. We never intended this femur transplantation model of bone marrow injury to replace more established models, such as chemotherapy or irradiation. In fact, we compared the effects of femur transplantation to localized bone irradiation on P-SSCs using our Periostin-Cre;Td-Tomato lineage tracing model. We found that irradiation does not induce the same migration of Tomato+ P-SSCs from the periosteum to the bone marrow cavity the way that femur transplantation, and cannot be used to demonstrate the plasticity of P-SSCs in the same way (see new Supplementary Figure S7D-E). Therefore, this appears to be a more severe form of bone marrow injury, and is not similar to other more established assays of bone marrow injury. We also added this discussion to the revised manuscript on p.14 and in the discussion section on p.17.

The authors perform some analysis that suggests that grafting a whole femur mimics BM regeneration, but there are many experiments missing from the manuscript that will be necessary to support the use of this model. To demonstrate that this new model mimics current BM regeneration models, the authors need to perform a careful examination of the early kinetics of hematopoietic recovery post-transplant. Complete blood counts should be performed on the grafts, focusing on white blood cells (particularly neutrophils), red blood cells, platelets, all critical indicators of BM regeneration. This analysis should be done at early time points that include weekly analysis for a minimum of 28 days following the graft. Additionally, understanding how and when the vasculature recovers is critical. This is particularly important because it is well-established that if there is a delay in vascular recovery, there is a delay in hematopoietic recovery. As mentioned above, a standard BM regeneration model should be used as a control.

We concur with the reviewer that hematopoietic recovery is a pivotal aspect of this model. We conducted a time-course analysis of bone marrow and HSC cellularity from day 0 to month 5 post-transplantation (Figure 1B). Furthermore, we evaluated the HSC capacities through bone marrow transplantation from grafted or host femurs (Figures 1D and 1E) and quantified the various hematopoietic cells in the graft after five months (Supplemental Figure 1). Furthermore, hematopoiesis occurring in the transplanted bone was comprehensively evaluated in another article, currently in revision and available in BioRxiv (Takeishi, S., Marchand, T., Koba, W. R., Borger, D. K., Xu, C., Guha, C., Bergman, A., Frenette, P. S., Gritsman, K., & Steidl, U. (2023). Haematopoietic stem cell numbers are not solely determined by niche availability. bioRxiv: the preprint server for biology, 2023.10.28.564559. https://doi.org/10.1101/2023.10.28.564559). We did not use another assay of bone marrow regeneration as a “control”, since we do not expect to see similar plasticity of periosteal SSCs in these models, such as with the localized irradiation model described in the new Figure S7D-E.

We agree with the reviewer that endothelial recovery is also likely to be very important for hematopoietic recovery in this model, but this was not the focus of this manuscript. The process of endothelial recovery is likely to be more complex than that of MSC recovery, as our findings indicate that the graft endothelium can arise from both the host and the graft femur (see Fig.2D). Consequently, further investigation into the mechanisms of endothelial recovery and its contribution to hematopoiesis in this experimental system will be an interesting focus of future work. We believe that this bone transplantation model represents a valuable tool for addressing questions regarding the origin and regeneration mechanisms of bone marrow endothelial cells.

The contribution of donor and host cells to the BM regeneration of the graft is interesting. Particularly, the chimerism of the vasculature. One can assume that for the graft to undergo BM regeneration, there needs to be the delivery of nutrients into the graft via the vasculature. The chimerism of the vascular network suggests that host endothelial cells anastomose with the graft. Host mice should have their vascular system labeled with a dye such as dextran to determine if anastomosis has occurred. If not, the authors need to explain how this graft survives up to 5 months. If anastomosis does occur, then it is very surprising that the hematopoietic system of the graft is not a chimera because this would essentially be a parabiosis model. This needs to be explained.

We have included additional images of bone sections from VE-cadherin-cre;tdTomato grafted femurs at 15 days, one month, and five months post transplantation in the new Figure S3. These images show extensive vascularization of the graft and proximity of UBC-GFP+ donor-derived vessels to VE-cadherin+ host-derived blood vessels in the bone marrow within one month, suggesting a potential anastomosis (Figure S2C). However, it is not surprising that hematopoiesis arises exclusively from the host, as we observed complete death of the hematopoietic cells and BM MSCs in the graft femur within the first 3 days of femur transplantation (see Figure S1A), and we do not see any significant hematopoietic recovery in the grafts until at least 2 months (see Fig.1B). Therefore, this is not similar to a parabiosis model, as confirmed by our chimerism studies shown in Figure 2D. In addition, these data are consistent with the results reported with the use of ossicles (doi:10.1038/nature09262; DOI 10.1016/j.cell.2007.08.025; doi:10.1038/nature07547).

Most of the data presented for the resistance of p-SSCs to stress suggests DNA damage response. Do p-SSCs demonstrate a higher ability to resolve DNA damage? Do they accumulate less DNA damage? Staining for DNA damage foci or performing comet assays could be done to further define the mechanism of stress resistance properties of p-SSCs.

This is an interesting question. In our RNA sequencing analysis of graft P-SSCs compared with host P-SSCs we did observe an upregulation of mismatch repair gene signatures by gene set enrichment analysis (GSEA) (new Figure S5C). Therefore, it is possible that P-SSCs do have an altered DNA damage response. However, we are unable to investigate this further at this time.

Given the importance of BM-MSCs in hematopoiesis and that the majority of the emerging BM-MSCs appear to be derived from p-SSCs, the authors should perform experiments to determine if p-SSC-derived BM-MSCs are critical regulators of BM regeneration. For example, the authors could test this by crossing the Postn-creER mice with iDTR mice to ablate these cells and see if recovery is inhibited or delayed. This should be done with the described periosteum-wrapped femur graft model as well as a control BM regeneration model. Demonstrating that the deletion of these cells affects BM regeneration in both models would further justify the physiological relevance and utility of the femur graft model.

We thank the reviewer for this excellent suggestion, and we agree that this is an important experiment. However, our attempts to ablate Postn+ cells using the iDTA system were limited by technical difficulties, which we are unable to address at this time.

Recommendations for the authors:

Reviewer #1 (Recommendations for the authors):

(1) In Figure 2C, the vascular network staining appears to be duplicated, suggesting a possible error in image capture. The authors should replace this image with a different field or an alternative picture to avoid confusion.

We thank the reviewer for noting this accidental duplication due to an image stitching problem. Figure 2C was replaced by a different image from the same experiment.

(2) For consistency and clarity, a scale bar should be included in Figure S3E to indicate that the magnification factors of the respective visual fields are identical.

We thank the reviewer for highlighting this point. The magnification used has been added in the revised Figure.

(3) In Figure S5B, the difference in normalized Opn mRNA expression relative to Gapdh between steady-state BM-MSCs and P-SSCs seems substantial, which contradicts the "ns" (not significant) label. The authors should verify the accuracy of this labeling.

We agree with the reviewer that this difference in what is now Figure S6B looks substantial. However, we confirmed that this difference is not statistically significant, likely due to the high variability between replicates in Opn expression in the steady state BM MSCs.

Reviewer #2 (Recommendations for the authors):

In order to strengthen the argument that P-SSCs are necessary for hematopoietic recovery, the authors should consider providing the following data:

(1) In the periosteal stripping experiments, the authors should show if periosteum-derived MSCs are present in the BM throughout the process of hematopoietic recovery (not just at the end of the experiment). If none are present at the end, that would mean that periosteum is not required for hematopoietic recovery, but would still suggest that it is required for optimal hematopoietic recovery. At early time points, it would also be very helpful to demonstrate the composition and amount of endothelium present in the marrow to determine if P-SSC migration and differentiation into MSCs depends on endothelial reconstitution.

To further examine the vascularization of the transplanted femur at an earlier time point, we have added additional images of grafted femur from VE-cadherin-cre;tdTomato at 15 days and one month post transplantation in the new Figure S3A and S3B. These images already show extensive vascularization of the graft periosteum stained with an anti-periostin antibody. In addition, we observed anastomoses of host VE-cadherin;Tmt+ blood vessels with graft ubc-GFP+ blood vessels in the grafted periosteum within one month (Figure S3C).

(2) Studies of the surgical periosteum grafts could benefit from histologic analysis of the BM and its MSC components at earlier time points following grafting since the data provided are only at 5 months. Such studies would allow a better appreciation of the relationship between P-SSC migration into the marrow and hematopoietic recovery.

We have performed histologic analysis of grafted femurs at multiple early time points, which shows expansion of P-SSCs and their migration into the bone marrow cavity (Figure 3C).

(3) Studies of stress responses preferably should be performed using intact bone and should characterize P-SSC and BM MSC apoptosis, cell cycle status, differentiation, etc, immediately following shifts to the stress conditions. These studies would be more compelling if performed using additional "stress" conditions likely to represent the graft environment.

This is an interesting suggestion. However, these types of studies would not be possible in intact bones ex vivo, as P-SSCs are known to migrate out of the bone in culture.

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Data Citations

    1. Marchand T, Akinnola M. 2023. Periosteal skeletal stem cells can migrate into the bone marrow and support hematopoiesis after injury. NCBI Gene Expression Omnibus. GSE222272 [DOI] [PMC free article] [PubMed]

    Supplementary Materials

    MDAR checklist
    Supplementary file 1. Antibodies used in flow cytometry experiments.
    Supplementary file 2. Sequences of primers used for RT-PCR .
    elife-101714-supp2.docx (15.9KB, docx)

    Data Availability Statement

    All RNA sequencing data are available under the SuperSeries dataset GSE222272 in GEO omnibus.

    The following dataset was generated:

    Marchand T, Akinnola M. 2023. Periosteal skeletal stem cells can migrate into the bone marrow and support hematopoiesis after injury. NCBI Gene Expression Omnibus. GSE222272


    Articles from eLife are provided here courtesy of eLife Sciences Publications, Ltd

    RESOURCES